September 2025
1. AL MAQRASHI ZAA, Kartolo A, Meyers BM
   Resectable locally advanced head and neck squamous cell carcinoma: cut first or immune checkpoint inhibitors first?
   Oral Oncol. 2025;170:107704.
   

   >> Share

   
   
2. CHENG H, Jiang M, Kim S, Moshiri A, et al
   Uncovering chromatin factor landscapes in head and neck squamous cell carcinoma.
   Oral Oncol. 2025;170:107687.
   

   >> Share

   
   
3. MISRA SR, Das R
   Financial instability, insurance, and transportation barriers in oral cancer care: contrasting perspectives between the United States and India.
   Oral Oncol. 2025;169:107692.
   

   >> Share

   
   
4. SAMUEL M
   Disparities in oral cancer screening in India: reflections on NFHS 5 evidence and pathways forward.
   Oral Oncol. 2025;169:107693.
   

   >> Share

   
   
5. SINDYA J, Rajanathadurai J, Perumal E
   Reflections on "Low skeletal muscle mass and not systemic inflammation is associated with complications after free forearm flap reconstruction in oral cancer patients".
   Oral Oncol. 2025;169:107691.
   

   >> Share

   
   
6. SASIKALA S, Sowmiya A, Usharani N
   Letter to the Editor: Salivary DNA methylation derived estimates of biological Aging, cellular frequency and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients.
   Oral Oncol. 2025;169:107668.
   

   >> Share

   
   
7. LUO L, Lu C, Feng H
   Refining SCCUP management: towards safe de-escalation in HPV-positive head and neck cancer-letter on Barrett et al.
   Oral Oncol. 2025;169:107681.
   

   >> Share

   
   
8. VENKATACHALAM DK, Kanimozhi K
   Letter to the Editor "Low skeletal muscle mass and not systemic inflammation is associated with complications after free forearm flap reconstruction in oral cancer patients".
   Oral Oncol. 2025;169:107679.
   

   >> Share

   
   
9. MISRA SR, Das R
   The imperative of careful selection and novel strategies: Comment on Mrosk et al.'s outcomes of primary chemoradiation for advanced oral cancer.
   Oral Oncol. 2025;169:107676.
   

   >> Share

   
   
10. KUMAR GN, Sangeetha S
    Comment on "Low skeletal muscle mass and not systemic inflammation is associated with complications after free forearm flap reconstruction in oral cancer patients".
    Oral Oncol. 2025 Sep 8:107666. doi: 10.1016/j.oraloncology.2025.107666.
    

    >> Share

    
    
11. XIAO X, Liu T, Song Y, Lu M, et al
    Evaluation on the prognostic significance of cervical occult metastasis in cN0 glottic laryngeal cancer.
    Oral Oncol. 2025;169:107648.
    

    >> Share

    
    
12. ZHANG D, Zhang J, Cai M
    Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
    Oral Oncol. 2025;169:107660.
    

    >> Share

    
    
13. ZHANG D, Zhang P, Cai M
    Letter to the Editor: Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
    Oral Oncol. 2025;169:107661.
    

    >> Share

    
    
14. DUAN Y
    Letter to the Editor: Oral cancer screening in India: A secondary analysis of disparities using national family health survey data.
    Oral Oncol. 2025;169:107657.
    

    >> Share

    
    
15. ZHANG D, Zhou Y, Cai M
    Letter to the Editor: Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
    Oral Oncol. 2025;169:107659.
    

    >> Share

    
    
16. MISRA SR, Das R
    Critical appraisal of "Oral cancer screening in India: A secondary analysis of disparities using national family health survey data".
    Oral Oncol. 2025;169:107653.
    

    >> Share

    
    
17. PENG X, Xie Y, Liu Y
    Comment on "Prediction of clinical outcomes of immune checkpoint inhibitors in advanced head and neck cancer directly from histopathology slides using inferred transcriptomics".
    Oral Oncol. 2025;169:107644.
    

    >> Share

    
    
18. BATOOL S, Hansen EE, Sethi RKV, Rettig EM, et al
    Financial instability, insurance, and transportation influence timely head and neck cancer care in the United States: Patient and healthcare worker perspectives.
    Oral Oncol. 2025;169:107607.
    

    >> Share

    
    
19. DUNN LA, Ho AL, Michel LS, Wong W, et al
    A phase 1/1b study of lenvatinib and cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2025;169:107524.
    

    >> Share

    
    
20. NOEL CW, Birkenbeuel J, Ozer E, Agrawal A, et al
    Patterns of referral and outcomes in oropharyngeal cancer management.
    Oral Oncol. 2025;168:107602.
    

    >> Share

    
    
21. GILI R, Morbini P, Bossi P
    PD-L1 Expression in head and neck squamous cell carcinoma: qualitative or quantitative assessment? Is that enough or we need something more?
    Oral Oncol. 2025;168:107606.
    

    >> Share

    
    
22. YANG J, Wu W, Liu J, Li J, et al
    Comprehensive integration of single-cell and bulk transcriptome to reveal plasma cell heterogeneity and a prognosis signature in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;168:107595.
    

    >> Share

    
    
23. KLEEBAYOON A, Wiwanitkit V
    Semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD): correspondence.
    Oral Oncol. 2025;169:107645.
    

    >> Share

    
    
24. BHAGIA P, Mukherjee A, Agarwal T, Giri S, et al
    Stroke risk after head and neck cancer diagnosis and treatment in a Real-World clinical cohort: Running title: Treatment in a Real-World clinical cohort.
    Oral Oncol. 2025;169:107599.
    

    >> Share

    
    August 2025
25. BARRETT TF, Apicelli AJ, Ramadan S, Pipkorn P, et al
    Management of HPV+ head and neck squamous cell carcinoma with unknown primary in the era of treatment de-escalation.
    Oral Oncol. 2025;169:107631.
    

    >> Share

    
    
26. ANSARI E, Carrillo Minulina N, van Es RJJ, Dieleman FJ, et al
    Low skeletal muscle mass and not systemic inflammation is associated with complications after free forearm flap reconstruction in oral cancer patients.
    Oral Oncol. 2025;169:107628.
    

    >> Share

    
    
27. DAI Y, Li W
    Comment on "Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD)" by Schroter et al.
    Oral Oncol. 2025;169:107640.
    

    >> Share

    
    
28. KANA L, Chamma B, Robinette N, Cramer JD, et al
    Pre-treatment PET/CT for head and neck squamous cell carcinoma: secondary analysis of a clinical trial.
    Oral Oncol. 2025;169:107633.
    

    >> Share

    
    
29. HUANG J, Yan X, Wang S, Huang S, et al
    Improvements to the LEF Self-Management study for head and neck cancer survivors - Letter on Deng et al.
    Oral Oncol. 2025;169:107639.
    

    >> Share

    
    
30. CAO J, Han W, Liu Y
    Letter to the editor: effects of diagnostic delays in head and neck cancer patients presenting to the emergency department.
    Oral Oncol. 2025;169:107624.
    

    >> Share

    
    
31. HUANG X, Gu X
    Comment on Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study.
    Oral Oncol. 2025;169:107626.
    

    >> Share

    
    
32. MISRA SR, Das R
    Insights on: "Social health at 5 years after diagnosis in head and neck cancer Survivors".
    Oral Oncol. 2025;169:107637.
    

    >> Share

    
    
33. BOSSI P, Kiyota N, Mesia R, Rosenberg AJ, et al
    Adverse event profiles and management of cisplatin-based chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a systematic review.
    Oral Oncol. 2025;169:107596.
    

    >> Share

    
    
34. TANG Y, Jin Q, Gan X
    Comment on "Social health at 5 years after diagnosis of head and neck cancer".
    Oral Oncol. 2025;169:107627.
    

    >> Share

    
    
35. RAHMAN R, Sheikh I, Merchant Y, Mathur A, et al
    Oral cancer screening in India: a secondary analysis of disparities using national family health survey data.
    Oral Oncol. 2025;169:107632.
    

    >> Share

    
    
36. DAI Y, Li WJ
    Comment on "Feasibility and preliminary efficacy of a lymphedema and fibrosis self-management program for head and neck cancer survivors: A pilot randomized controlled trial" by Deng J et al.
    Oral Oncol. 2025;169:107613.
    

    >> Share

    
    
37. CHEN Y, Yan Y
    Comment on "A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus".
    Oral Oncol. 2025;169:107614.
    

    >> Share

    
    
38. LUO R, Wu J, Zhong W, Ai K, et al
    Letter to the editor - Commentary on "A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus".
    Oral Oncol. 2025;169:107610.
    

    >> Share

    
    
39. ZHANG J, Liu DM
    Advancing self-management for head and neck cancer-related lymphedema: A promising step forward.
    Oral Oncol. 2025;169:107611.
    

    >> Share

    
    
40. SCHROTER P, Christ LV, Dvornikovich K, Stritzke F, et al
    Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
    Oral Oncol. 2025;169:107604.
    

    >> Share

    
    
41. COLAK G, Demir B
    Letter to the Editor: "Effects of diagnostic delays in head and neck cancer patients presenting to the emergency department".
    Oral Oncol. 2025;168:107579.
    

    >> Share

    
    
42. TOSONI A, Di Nunno V, Carlini A, Gatto L, et al
    The role of systemic therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma progressed to immunotherapy: A systematic review and meta analysis.
    Oral Oncol. 2025;168:107582.
    

    >> Share

    
    
43. ASHOK A, Dimitri S, Plonowska-Hirschfeld K, Wu MP, et al
    Establishing an integrated approach to head and neck cancer treatment and prevention: The Robert Ebert and Greg Stubblefield Head and Neck Tumor Center Model.
    Oral Oncol. 2025;168:107591.
    

    >> Share

    
    
44. LAVANYA K, Sathishkumar K, Nallusamy D
    Letter to the editor: A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus.
    Oral Oncol. 2025;168:107590.
    

    >> Share

    
    
45. HONGO T, Hirano Y, Tarutani Y, Omori H, et al
    Prospective study of algorithm-based chemoradioselection to optimize treatment intensity for advanced head and neck cancer.
    Oral Oncol. 2025;168:107585.
    

    >> Share

    
    
46. KOKER G, Ozcelik G
    Comment on: "Cisplatin ototoxicity and hydration schedules''.
    Oral Oncol. 2025;168:107545.
    

    >> Share

    
    
47. DENG J, Murphy BA, Andersen LP, McMenamin E, et al
    Feasibility and preliminary efficacy of a lymphedema and fibrosis self-management program for head and neck cancer survivors: a pilot randomized controlled trial.
    Oral Oncol. 2025;168:107556.
    

    >> Share

    
    
48. SUDARSON J
    Commentary on "molecular features of T and N stage progression in laryngeal cancer".
    Oral Oncol. 2025;168:107587.
    

    >> Share

    
    
49. YU Z, Zhuang Z, Zhao X, Chi H, et al
    Advancing AI-driven pathology in oral cancer: opportunities for enhanced TIL assessment and clinical integration.
    Oral Oncol. 2025;168:107586.
    

    >> Share

    
    
50. ASHOKKUMAR K
    Letter to the editor - a preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus.
    Oral Oncol. 2025;168:107580.
    

    >> Share

    
    
51. KRISHNAN M, Jothishanmugam A, Mari A, Babu S, et al
    Preserving the mandible, protecting the patient: A commentary on fracture risk following marginal mandibulectomy in head and neck cancer.
    Oral Oncol. 2025;168:107575.
    

    >> Share

    
    
52. MATSUDA Y, Fujioka-Kobayashi M, Tatsumi H, Osako-Sonoyama R, et al
    Factors associated with postoperative oral dysfunction in patients with oral cancer: a structural equation modeling study.
    Oral Oncol. 2025;168:107577.
    

    >> Share

    
    
53. MULARONI F, Marchi F, Gaudioso P, Taboni S, et al
    Selected laryngeal squamous cell carcinomas with laryngeal mobility impairment are suitable for curative larynx-preservation treatment: A multi-institutional study on 406 patients from the ARYFIX collaborative group.
    Oral Oncol. 2025;167:107466.
    

    >> Share

    
    
54. MORES AL, Lima de Araujo CA, de Freitas Busnardo F, Cardili L, et al
    Cutaneous metastasis of oropharyngeal squamous cell carcinoma: A case report.
    Oral Oncol. 2025;167:107438.
    

    >> Share

    
    
55. SEDASSARI BT, Celin MF, Pigatti FM
    SMARCB1-deficient sinonasal carcinoma with oral involvement: A potential mimicker of salivary-type carcinomas.
    Oral Oncol. 2025;167:107435.
    

    >> Share

    
    
56. TONSBEEK AM, Hundepool CA, van der Oest M, Offerman MPJ, et al
    Life following total laryngectomy: mixed-model analyses of longitudinal patient-reported outcomes in a prospective cohort.
    Oral Oncol. 2025;167:107431.
    

    >> Share

    
    
57. PERYASSU BC, Nicolau-Neto P, da Costa EWE, Santos IC, et al
    Assessing the prognostic significance and predictive features of cervical occult metastasis in glottic laryngeal squamous cell carcinoma.
    Oral Oncol. 2025;167:107429.
    

    >> Share

    
    
58. DOLL C, Hofmann E, Trelinska-Finger A, Heiland M, et al
    Benefit from adjuvant radiotherapy in early-stage oral cavity and oropharyngeal cancer with solitary ipsilateral lymph node metastasis - A population-based study on German cancer registry data.
    Oral Oncol. 2025;167:107384.
    

    >> Share

    
    
59. GUZZO M, Bianchi R, Colombo S, Santamato F, et al
    Mandibular swing approach: 25 years of experience at Istituto Nazionale Tumori of Milan.
    Oral Oncol. 2025;167:107405.
    

    >> Share

    
    
60. TONG JY, Brimanson K, Moyer K, Wolf J, et al
    Margin analysis of radical tonsillectomy specimens following transoral robotic surgery.
    Oral Oncol. 2025;167:107403.
    

    >> Share

    
    
61. LUNA-ORTIZ K, Guillen-Hernandez GA, Cano-Valdez AM, Alvarez-Avitia MA, et al
    Poorly differentiated ceruminous adenocarcinoma of the external auditory canal: Letter to the editor.
    Oral Oncol. 2025;168:107544.
    

    >> Share

    
    
62. JENNIFER LG, Larnaudie A, Bene MC, Cocherie T, et al
    Relationships between oral microbiome and head and neck squamous cell carcinoma: a systematic review.
    Oral Oncol. 2025;168:107571.
    

    >> Share

    
    
63. HUMBERT M, Perreard M, Licaj I, Bouhnik AD, et al
    Social health at 5 years after diagnosis of head and neck cancer.
    Oral Oncol. 2025;168:107567.
    

    >> Share

    
    July 2025
64. ELIA A, Tirosh O, Dinstag G, Gugel L, et al
    Prediction of clinical outcomes of immune checkpoint inhibitors in advanced head and neck cancer directly from histopathology slides using inferred transcriptomics.
    Oral Oncol. 2025;168:107536.
    

    >> Share

    
    
65. LI Y, Xiao L, Xie R
    Mitigating survival disparities in head and neck cancer: urgent need to reduce ED-based biopsy delays.
    Oral Oncol. 2025;168:107549.
    

    >> Share

    
    
66. SHARFUNNISA SH
    Letter to the editor "reframing nutritional support in head and neck cancer: insights from a prospective cohort study".
    Oral Oncol. 2025;168:107563.
    

    >> Share

    
    
67. ZHANG D, Cai M
    Letter to the Editor: A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus.
    Oral Oncol. 2025;168:107558.
    

    >> Share

    
    
68. RAJASEKAR A
    Letter to the Editor: HCV infection in head and neck cancer patients: Implications for screening and prognosis in a low prevalence setting.
    Oral Oncol. 2025;168:107561.
    

    >> Share

    
    
69. HIEROMNIMON HM, Trzcinska A, Wen FT, Howard FM, et al
    Corrigendum to "Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas". [Oral Oncol. 163 (2025) 107207].
    Oral Oncol. 2025 Jul 27:107510. doi: 10.1016/j.oraloncology.2025.107510.
    

    >> Share

    
    
70. KRISHNAN M, Babu S
    Commentary on Lee et al: From crisis to diagnosis: redefining the emergency department's role in head and neck cancer detection.
    Oral Oncol. 2025;168:107546.
    

    >> Share

    
    
71. PENG J, Liang Z, Wang J, Wang G, et al
    Comment on effects of diagnostic delays in head and neck cancer patients presenting to the emergency department.
    Oral Oncol. 2025;168:107537.
    

    >> Share

    
    
72. KRISHNAN M, Babu S
    Letter to the editor: redefining surgical paradigms in isthmic papillary thyroid carcinoma: a timely reappraisal.
    Oral Oncol. 2025;168:107562.
    

    >> Share

    
    
73. NARENKUMAR J, Parthipan P
    Letter to the Editor: Impact of the COVID-19 pandemic on diagnosis and disease stage in HPV-positive oropharyngeal cancer: insights and future directions.
    Oral Oncol. 2025;168:107541.
    

    >> Share

    
    
74. D'ANDREA C, Marhic A, Leveque E, Thureau S, et al
    Risk factors for fractures after marginal mandibulectomy for head and neck cancer multicentre study.
    Oral Oncol. 2025;168:107512.
    

    >> Share

    
    
75. BABU S, Krishnan M, Ravi PS
    "Commentary on: Long-term health-related quality of life in oral cancer survivors following microvascular tongue reconstruction".
    Oral Oncol. 2025;168:107552.
    

    >> Share

    
    
76. KRISHNAN M, Chawla KK, Babu S, D S, et al
    Letter to the editor: Molecular stratification in papillary thyroid carcinoma: Should RET fusions redefine aggressiveness in the post-BRAF era?
    Oral Oncol. 2025;168:107543.
    

    >> Share

    
    
77. MORCOM CR, Williams CMD, Al-Qadami G, Vieyra CP, et al
    The biological mechanisms underpinning nutritional and health-related consequences of mucositis in head and neck cancer - A review.
    Oral Oncol. 2025;168:107548.
    

    >> Share

    
    
78. ARULMOORTHY MP
    Navigating the diagnostic delay: optimizing timely biopsy and integrating NIR-based technologies for head and neck cancer.
    Oral Oncol. 2025;168:107518.
    

    >> Share

    
    
79. SHARFUNNISA SH, Rahmathullah A
    Letter to the editor "Integrating nutritional profiling into immunotherapy: A modifiable predictor of outcomes in head and neck Cancer".
    Oral Oncol. 2025;168:107539.
    

    >> Share

    
    
80. BABU S, Solomon A, Krishnan M
    Commentary on "Massive nasal bleeding in nasopharyngeal carcinoma: Incidence, risk predictors, and survival impact".
    Oral Oncol. 2025;168:107528.
    

    >> Share

    
    
81. JEYARAJ G
    Commentary on, "Effects of diagnostic delays in head and neck cancer patients presenting to the emergency department".
    Oral Oncol. 2025;168:107532.
    

    >> Share

    
    
82. ABILAJI S, Parthipan P
    Letter to the Editor: Evaluating the risk-modifying effects of HSV-1 and HSV-2 on head and neck cancer in relation to tobacco, alcohol, and HPV-16.
    Oral Oncol. 2025;168:107516.
    

    >> Share

    
    
83. CHAWLA JPS, Madan GK
    Comment on "Current status of circulating tumour DNA and circulating cell alterations in HPV-associated head and neck cancer".
    Oral Oncol. 2025;168:107526.
    

    >> Share

    
    
84. ZHU J, Xu J, Qu H, Hao J, et al
    A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus.
    Oral Oncol. 2025;168:107511.
    

    >> Share

    
    
85. LEE MY, Huynh JD, Kim DD, Sunwoo JB, et al
    Effects of diagnostic delays in head and neck cancer patients presenting to the emergency department.
    Oral Oncol. 2025;168:107467.
    

    >> Share

    
    
86. YANG Z, Lin B, Xie R
    Microvascular tongue reconstruction in oral cancer: Long-term functional outcomes and quality of life considerations.
    Oral Oncol. 2025;167:107490.
    

    >> Share

    
    
87. ZHANG Y, Liang R, Lai P
    Comment on "The association between health-related quality of life and five-year overall survival among head and neck cancer patients: A prospective cohort study".
    Oral Oncol. 2025;167:107491.
    

    >> Share

    
    
88. JEYARAJ G
    Commentary on, "Transoral endoscopic thyroidectomy vestibular approach for pT1b papillary thyroid carcinoma: Surgical and oncological outcomes.".
    Oral Oncol. 2025;167:107487.
    

    >> Share

    
    
89. RAJATHIRAJAN SD
    Commentary on, "Impact of HIV status on overall survival in head and neck cancers by anatomical site and stage: A multi-center cohort study".
    Oral Oncol. 2025;167:107483.
    

    >> Share

    
    
90. JEYARAJ G
    Commentary on, "Massive nasal bleeding in nasopharyngeal Carcinoma: Incidence, risk Predictors, and survival impact.".
    Oral Oncol. 2025;167:107488.
    

    >> Share

    
    
91. CHENG HS, Lin TY, Twu CW, Lin PJ, et al
    Corrigendum to "Massive nasal bleeding in nasopharyngeal carcinoma: incidence, risk predictors, and survival impact" [Oral Oncol. 167 (2025) 107456].
    Oral Oncol. 2025 Jul 4:107465. doi: 10.1016/j.oraloncology.2025.107465.
    

    >> Share

    
    
92. RAJATHIRAJAN SD
    Commentary on, "Computed tomography radiomics-based cross-sectional detection of mandibular osteoradionecrosis in head and neck cancer survivors".
    Oral Oncol. 2025;167:107472.
    

    >> Share

    
    
93. HU A, Wen X, Tian J, Wang Z, et al
    RET fusion rather than BRAF mutation confers a higher risk of aggressiveness and recurrence in papillary thyroid carcinoma.
    Oral Oncol. 2025;167:107464.
    

    >> Share

    
    
94. RIJKEN JA, de Ridder M, Devriese LA, Breimer GE, et al
    Long-term survival after multimodal treatment of sinonasal NUT carcinoma: a case report.
    Oral Oncol. 2025;166:107392.
    

    >> Share

    
    
95. RONDI P, Mattavelli D, Rampinelli V, Schreiber A, et al
    The role of volumetry in sinonasal cancer response assessment to induction chemotherapy, results from two phase II non-randomized controlled prospective multicentric trials: SINTART-1 and SINTART-2.
    Oral Oncol. 2025;166:107388.
    

    >> Share

    
    
96. SOMAY E, Bascil S, Topkan E, Selek U, et al
    Re: "Computed tomography radiomics-based cross-sectional detection of mandibular osteoradionecrosis in head and neck cancer survivors" by Kamel et al.
    Oral Oncol. 2025;167:107457.
    

    >> Share

    
    June 2025
97. MALGAVE DS, Hartman CM, Kramer JR, Richardson PA, et al
    Impact of HIV status on overall survival in head and neck cancers by anatomical site and stage: A multi-center cohort study.
    Oral Oncol. 2025;167:107446.
    

    >> Share

    
    
98. EICKELSCHULTE S, Starus A, Murray DH, Keyser KA, et al
    Analytical and clinical performance validation of HPV-SEQ, a novel NGS-based liquid biopsy platform for detection and quantification of human papilloma virus circulating tumor DNA.
    Oral Oncol. 2025;167:107445.
    

    >> Share

    
    
99. RAJATHIRAJAN SD
    Commentary on, "Optimal induction chemotherapy courses in nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA and AJCC staging".
    Oral Oncol. 2025;167:107453.
    

    >> Share

    
    
100. CHENG HS, Lin TY, Twu CW, Lin PJ, et al
     Massive nasal bleeding in nasopharyngeal Carcinoma: Incidence, risk Predictors, and survival impact: Running title: Massive nasal bleeding in NPC.
     Oral Oncol. 2025;167:107456.
     

     >> Share

     
     
101. DAUNGSUPAWONG H, Wiwanitkit V
     Optimal induction chemotherapy courses in nasopharyngeal carcinoma in the IMRT era: Comment.
     Oral Oncol. 2025;167:107454.
     

     >> Share

     
     
102. SAMUEL CHAN SW, Amer Al Maqrashi ZA, Kim DH, Choi D, et al
     Induction chemotherapy and immunotherapy followed by chemo-radiotherapy in incurable advanced head and neck squamous cell carcinoma: A case-series.
     Oral Oncol. 2025;167:107439.
     

     >> Share

     
     
103. NGO DQ, Truong DS, Le DT, Hoang TM, et al
     Transoral endoscopic thyroidectomy vestibular approach for pT1b papillary thyroid carcinoma: surgical and oncological outcomes.
     Oral Oncol. 2025;167:107406.
     

     >> Share

     
     
104. ARAUJO M, Bouassaly J, Farshadi F, Hier M, et al
     Current status of circulating tumor DNA and circulating cell alterations in HPV-associated head and neck cancer.
     Oral Oncol. 2025;167:107417.
     

     >> Share

     
     
105. KAMEL S, Humbert-Vidan L, Kaffey Z, Mirbahaeddin S, et al
     Computed tomography radiomics-based cross-sectional detection of mandibular osteoradionecrosis in head and neck cancer survivors.
     Oral Oncol. 2025;167:107337.
     

     >> Share

     
     
106. MAK CH, Cao LM, Luo HY, Zhou K, et al
     Postoperative complications of neck dissection for head and neck squamous cell carcinoma: a systematic review and meta-analysis.
     Oral Oncol. 2025;167:107430.
     

     >> Share

     
     
107. YANG X, Li R
     Reconsidering the prognostic value of HRQOL in head and neck cancer.
     Oral Oncol. 2025;167:107421.
     

     >> Share

     
     
108. YAN Y, Wang Z, Sun Y
     Comment on: Margins do not impact recurrence and survival in advanced laryngeal cancer-A retrospective cohort analysis.
     Oral Oncol. 2025;167:107427.
     

     >> Share

     
     
109. LIANG YJ, Luo MJ, Wen DX, Wang P, et al
     Optimal induction chemotherapy courses in nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA and AJCC staging.
     Oral Oncol. 2025;167:107404.
     

     >> Share

     
     
110. KIM MJ, Koo BS, Cho KJ, Lee SH, et al
     Health-related quality-of-life assessment in patients with oropharyngeal cancer: A comparison of EQ-5D-5L and EORTC instruments.
     Oral Oncol. 2025;165:107342.
     

     >> Share

     
     
111. GARSET-ZAMANI M, Makouei F, Agander TK, Lelkaitis G, et al
     Feasibility of 3D ultrasound for intraoperative tumor margin assessment in transoral robotic surgery for oropharyngeal squamous cell carcinoma: A pilot study.
     Oral Oncol. 2025;165:107330.
     

     >> Share

     
     
112. KUMARI S, Mishra S, Ali W, Singh US, et al
     Implication of circulating miRNAs as potential diagnostic biomarker in oropharyngeal squamous cell Carcinoma: Association with Human Papilloma Virus.
     Oral Oncol. 2025;165:107305.
     

     >> Share

     
     
113. JANG HB, Lee DH, Lim SC
     Treatment outcomes of sinonasal adenoid cystic carcinoma: a single-center experience.
     Oral Oncol. 2025;165:107317.
     

     >> Share

     
     
114. CHELVARAJAH RC, Liu Y, Su J, Abdalaty AH, et al
     Factors associated with detection of oligometastatic recurrence and outcome following definitive (Chemo)radiotherapy for oropharyngeal carcinoma.
     Oral Oncol. 2025;165:107310.
     

     >> Share

     
     May 2025
115. HINTZE JM, Cleere E, Soo A, Timon C, et al
     Margins do not impact recurrence and survival in advanced laryngeal cancer - A retrospective cohort analysis.
     Oral Oncol. 2025;167:107402.
     

     >> Share

     
     
116. BAIJU DC, Ravi J, Sarma M, Sureshan M, et al
     Detection of hotspot mutations in oral cancer through Ion AmpliSeq cancer hotspot panel v.2.0: A circulating DNA fragmentomics approach in the Northeast Indian population.
     Oral Oncol. 2025;166:107387.
     

     >> Share

     
     
117. JEYARAJ G
     Commentary on, "The association between health-related quality of life and five-year overall survival among head and neck cancer patients: A prospective cohort study".
     Oral Oncol. 2025;166:107401.
     

     >> Share

     
     
118. LIU X, Xue S
     Comment on: Risk factors of lymph node metastasis in the diffuse sclerosing variant of papillary thyroid carcinoma compared with conventional papillary thyroidcarcinoma in pediatric populations.
     Oral Oncol. 2025;166:107368.
     

     >> Share

     
     
119. VERDONCK-DE LEEUW IM, Lissenberg-Witte BI, de Bree R, Buffart LM, et al
     The association between health-related quality of life and five-year overall survival among head and neck cancer patients: A prospective cohort study.
     Oral Oncol. 2025;166:107367.
     

     >> Share

     
     
120. OLSON B, Bogan A, Abdel-Halim CN, Rolle-McFarland D, et al
     Identification of clinical and pathologic features associated with extranodal extension in patients with HPV-mediated oropharyngeal squamous cell carcinoma.
     Oral Oncol. 2025;166:107308.
     

     >> Share

     
     
121. TONSBEEK AM, van der Lely JN, Bulstra L, Venema J, et al
     Long-term health-related quality of life in oral cancer survivors following microvascular tongue reconstruction.
     Oral Oncol. 2025;166:107363.
     

     >> Share

     
     
122. MALI SB
     Corrigendum to "Review of STAT3 (Signal Transducers and Activators of Transcription) in head and neck cancer" [Oral Oncol. 51 (2015) 565-569].
     Oral Oncol. 2025 May 10:107357. doi: 10.1016/j.oraloncology.2025.107357.
     

     >> Share

     
     
123. MALI SB
     Corrigendum to "RNA interference in oral cancer" [Oral Oncol. 51 (2015) e2-e3].
     Oral Oncol. 2025 May 9:107358. doi: 10.1016/j.oraloncology.2025.107358.
     

     >> Share

     
     
124. SHAIKH N, Pandey M, Manna S, Gawde J, et al
     Evaluating the prognostic value of tumor-derived circulating endothelial cells and their progenitors in platinum-refractory oral cancer patients for response to triple metronomic therapy.
     Oral Oncol. 2025;165:107346.
     

     >> Share

     
     
125. COSTANTINO A, Haughey BH, Alamoudi U, Magnuson JS, et al
     Prognostic significance of distant metastasis site at diagnosis in HPV-related oropharyngeal cancer.
     Oral Oncol. 2025;165:107361.
     

     >> Share

     
     
126. ONAGA R, Enokida T, Kuno H, Hiyama T, et al
     Significance of imaging-detected extranodal extension in locally advanced squamous cell carcinoma of the head and neck treated with induction chemotherapy followed by chemoradiotherapy.
     Oral Oncol. 2025;165:107351.
     

     >> Share

     
     
127. ZHU X, Xu H, Zhao Y, Diao W, et al
     Single-cell transcriptomics reveal the effects of chemoimmunotherapy on hypopharyngeal cancer and its tumor microenvironment.
     Oral Oncol. 2025;165:107347.
     

     >> Share

     
     
128. PEI Y, Yang Z, Mao Y, Chen X, et al
     Evolving dynamics in clinical trials for oral cancer: Trends, treatment modalities, and future directions.
     Oral Oncol. 2025;165:107333.
     

     >> Share

     
     
129. XIAO X, Liu T, Lu M, Song Z, et al
     Comment on the role of lymph node level ratio in predicting prognosis of pN1 head and neck squamous cell carcinoma.
     Oral Oncol. 2025;165:107344.
     

     >> Share

     
     
130. CHENNAREDDY S, Chen S, Levinson C, Genden EM, et al
     Circulating tumor DNA in human papillomavirus-associated oropharyngeal cancer management: A systematic review.
     Oral Oncol. 2025;164:107262.
     

     >> Share

     
     
131. MARCHI F, Del Bon F, Chu F, Sampieri C, et al
     Refining prognostic subcategories in intermediate-advanced glottic cancer: A multicentric study on 637 patients treated by transoral laser microsurgery.
     Oral Oncol. 2025;164:107264.
     

     >> Share

     
     
132. CANALI L, Russo E, Pangallo S, Bussu F, et al
     Regional disease control in nasal vestibule squamous cell carcinoma: Systematic review and meta-analysis.
     Oral Oncol. 2025;164:107270.
     

     >> Share

     
     
133. MOTTA G, Magno C, Castagna L, De Berardinis T, et al
     Endoscope-assisted trans-oral approach (EATA) to remove a rare pleomorphic adenoma of the nasopharynx.
     Oral Oncol. 2025;164:107260.
     

     >> Share

     
     
134. BEDDOK A, Popovtzer A, Calugaru V, Fontaine M, et al
     Proton therapy for primary and recurrent HPV-related oropharyngeal cancer.
     Oral Oncol. 2025;165:107309.
     

     >> Share

     
     April 2025
135. MALI SB
     Corrigendum to "Proteomics for oral cancer" [Oral Oncol. 50(11) (2014) e67].
     Oral Oncol. 2025 Apr 30:107338. doi: 10.1016/j.oraloncology.2025.107338.
     

     >> Share

     
     
136. CITRO S, Ghiani L, Doni M, Miccolo C, et al
     HPV-mediated PARP1 regulation and drug sensitization in head and neck cancer.
     Oral Oncol. 2025;165:107307.
     

     >> Share

     
     
137. SILVA CUNHA JL
     Comment on "Histological tumor necrosis predicts decreased survival after neoadjuvant chemotherapy in head and neck squamous cell carcinoma".
     Oral Oncol. 2025;165:107336.
     

     >> Share

     
     
138. AL FADEL AM, Jakobsen KK, Jensen LH, Carlander AF, et al
     The epidemiological trends and survival of HPV-related oropharyngeal cancer other than tonsils and base of tongue - a systematic review and meta-analysis.
     Oral Oncol. 2025;165:107311.
     

     >> Share

     
     
139. ARDILA CM
     Enhancing the scope and impact of photobiomodulation research in head and neck cancer therapy.
     Oral Oncol. 2025;165:107303.
     

     >> Share

     
     
140. JEYARAJ G
     Commentary on, "Molecular features of T and N stage progression in laryngeal cancer.".
     Oral Oncol. 2025;165:107331.
     

     >> Share

     
     
141. BARCELONA MVN, Waldron J, Sullivan BO, Su J, et al
     Outcomes following IMRT alone in head and neck squamous cell carcinoma ordinarily managed with concurrent chemo-radiotherapy.
     Oral Oncol. 2025;165:107299.
     

     >> Share

     
     
142. YAO CMKL, Hueniken K, Huang SH, Liu G, et al
     Development of a patient reported outcomes based machine learning model to predict recurrences in head and neck cancer.
     Oral Oncol. 2025;165:107304.
     

     >> Share

     
     
143. JEYARA G
     Commentary on, "Risk factors and a risk assessment model for venous thromboembolism in head and neck cancer surgery.".
     Oral Oncol. 2025;165:107320.
     

     >> Share

     
     
144. ZHOU P, Zhu Y, Xu B, Jiang X, et al
     Cavernous sinus syndrome in a patient with occult nasopharyngeal carcinoma: A diagnostic challenge.
     Oral Oncol. 2025;165:107316.
     

     >> Share

     
     
145. COSTANTINO A, Sampieri C, Haughey BH, Alamoudi U, et al
     Adjuvant treatment in elderly patients undergoing transoral surgery for HPV-related oropharyngeal cancer.
     Oral Oncol. 2025;165:107312.
     

     >> Share

     
     
146. KOSKENNIEMI AR, Huusko T, Routila J, Jalkanen S, et al
     Histological tumor necrosis predicts decreased survival after neoadjuvant chemotherapy in head and neck squamous cell carcinoma.
     Oral Oncol. 2025;165:107287.
     

     >> Share

     
     
147. JEYARAJ G
     Commentary on, "Effect of Enhanced Recovery After Radiotherapy (ERAR) on the quality of life in patients with nasopharyngeal carcinoma after radiotherapy: A randomized controlled trial".
     Oral Oncol. 2025;165:107302.
     

     >> Share

     
     
148. LI N, Zeng PYF, Kim HAJ, Karimi A, et al
     Molecular features of T and N stage progression in laryngeal cancer.
     Oral Oncol. 2025;165:107283.
     

     >> Share

     
     
149. BURGER AVM, Koot MA, van Balen DEM, Schaeffers AWMA, et al
     Comparison of cisplatin-induced hearing loss in different durations of infusion and volume of hydration schedules in head and neck squamous cell carcinoma patients treated with cisplatin-based chemoradiation.
     Oral Oncol. 2025;164:107246.
     

     >> Share

     
     
150. HANNA GJ, Zheng D, Gao W, Hair GM, et al
     Corrigendum to "PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S." [Oral Oncol. 161 (2025) 107146].
     Oral Oncol. 2025 Apr 11:107292. doi: 10.1016/j.oraloncology.2025.107292.
     

     >> Share

     
     
151. MA J, Brooks C, Tasoulas J, Wind LS, et al
     Revisiting the use of capecitabine in the era of immunotherapy: Efficacy as second-line and later therapy in recurrent/metastatic head and neck squamous cell carcinoma.
     Oral Oncol. 2025;164:107293.
     

     >> Share

     
     
152. SLATER NN, Herberger L, Farsi S, Rogers AL, et al
     Assessing barriers to adjuvant therapy among patients with head and neck cancer in Arkansas.
     Oral Oncol. 2025;164:107290.
     

     >> Share

     
     
153. XIAO J, You M, Song Y, Gao R, et al
     Risk factors and a risk assessment model for venous thromboembolism in head and neck cancer surgery.
     Oral Oncol. 2025;164:107288.
     

     >> Share

     
     
154. VIANNA CAMOLESI GC, Prado-Pena IB, Gomez-Caamano A, Victoria-Fernandez C, et al
     Photobiomodulation for the prevention of oral side effects secondary to head and neck cancer therapy: results of a randomised, single-blind clinical trial.
     Oral Oncol. 2025;164:107266.
     

     >> Share

     
     
155. JEYARAJ G
     Commentary on, "Evaluation of a comprehensive set of normal tissue complication probability models for patients with head and neck cancer in an international cohort".
     Oral Oncol. 2025;164:107285.
     

     >> Share

     
     
156. ROSING F, Plath M, Proctor T, Hofler D, et al
     Post-treatment monitoring of surgically treated oropharyngeal squamous cell carcinoma patients using human papillomavirus cell-free DNA.
     Oral Oncol. 2025;163:107225.
     

     >> Share

     
     March 2025
157. LIN N, Zhou X, Wang Y, Zhou J, et al
     Effect of enhanced recovery after radiotherapy (ERAR) on the quality of life in patients with nasopharyngeal carcinoma after radiotherapy: A randomized controlled trial.
     Oral Oncol. 2025;164:107269.
     

     >> Share

     
     
158. JEYARAJ G
     Commentary on, "Thyroid volumes after intensity-modulated radiotherapy as predictors of radiation-induced hypothyroidism in nasopharyngeal carcinoma: A retrospective study".
     Oral Oncol. 2025;163:107256.
     

     >> Share

     
     
159. ARDILA CM, Yadalam PK
     AI-driven histopathologic insights in HPV-positive head and neck squamous cell carcinomas.
     Oral Oncol. 2025;163:107261.
     

     >> Share

     
     
160. MATHEW JM, Busca I, Baskurt Z, Giuliani M, et al
     Changes in unmet needs after treatment for head and neck cancers - A prospective longitudinal cohort study.
     Oral Oncol. 2025;163:107250.
     

     >> Share

     
     
161. DONG Z, Wang GY, Qin GJ, Dai DY, et al
     Thyroid volumes after intensity-modulated radiotherapy as predictors of radiation-induced hypothyroidism in nasopharyngeal carcinoma: A retrospective study.
     Oral Oncol. 2025;163:107223.
     

     >> Share

     
     
162. LORENZ FJ, Kharouta M, Mahase SS, Goyal N, et al
     Hospital-Based Registry Analysis of Staging Efficacy and Proposed Staging Subclassification for Stage I HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
     Oral Oncol. 2025;163:107251.
     

     >> Share

     
     
163. PETRELLI F, Lorini L, Paderno A, Carioli D, et al
     Treatment of primary tumor in metastatic head and neck Carcinoma: A systematic review and Meta-Analysis.
     Oral Oncol. 2025;163:107248.
     

     >> Share

     
     
164. HIEROMNIMON HM, Trzcinska A, Wen FT, Howard FM, et al
     Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas.
     Oral Oncol. 2025;163:107207.
     

     >> Share

     
     
165. GAZZINI L, Festa BM, Calabrese L
     Elective neck dissection: Are we bound to outdated concepts?
     Oral Oncol. 2025;163:107245.
     

     >> Share

     
     
166. WU WJ, An PG, Liu Q, Zhang ZQ, et al
     Neoadjuvant chemoimmunotherapy brings superior quality of life of patients with locally advanced oral or oropharyngeal cancer: A propensity score-matched analysis.
     Oral Oncol. 2025;162:107218.
     

     >> Share

     
     
167. YANG F, Peng W, Wei H, Li X, et al
     Model-free parameters derived from intravoxel inherent motion combined with tumor aggressiveness indicators in predicting 5-year treatment outcome in NPC.
     Oral Oncol. 2025;162:107187.
     

     >> Share

     
     
168. YE Z, Li X, Xie F, Sun J, et al
     A single-cell sequencing-based analysis of a 13-year-old with maxillary sinus NUT carcinoma.
     Oral Oncol. 2025;162:107185.
     

     >> Share

     
     
169. CHARLTON A, Mughal Z, Sharin F, Sahota RB, et al
     Prevalence of synchronous bilateral/contralateral tonsil carcinoma: A systematic review and meta-analysis.
     Oral Oncol. 2025;162:107180.
     

     >> Share

     
     
170. DE VETTE SPM, van Rijn-Dekker MI, Van den Bosch L, Keijzer K, et al
     Evaluation of a comprehensive set of normal tissue complication probability models for patients with head and neck cancer in an international cohort.
     Oral Oncol. 2025;163:107224.
     

     >> Share

     
     
171. MIYAGUCHI J, Shiga K, Katagiri K, Saito D, et al
     Efficacy of boron neutron capture therapy (BNCT) for patients with oral cancer.
     Oral Oncol. 2025;163:107228.
     

     >> Share

     
     February 2025
172. WICZUK-WICZEWSKA M, Bernaciak J, Nogal P, Bugaj A, et al
     Squamous cell carcinoma in the posterior larynx: A rare localization of supraglottic T1 laryngeal cancer. Case report.
     Oral Oncol. 2025;163:107227.
     

     >> Share

     
     
173. JEYARAJ G
     Letter to the editor, "Mitoxantrone hydrochloride liposome injection for the treatment of Recurrent/Metastatic head and neck squamous cell carcinoma: A multicenter, open-label, single-arm, phase 1b study.".
     Oral Oncol. 2025;163:107231.
     

     >> Share

     
     
174. TINO RB, Roach MA, Fuentes GD, Agrawal A, et al
     Response to recent comments on "Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy".
     Oral Oncol. 2025;162:107220.
     

     >> Share

     
     
175. MEEKER BS MO, Katragadda A, Alsavaf MB, Birkenbeuel J, et al
     Dysphagia in head and neck cancer patients with evidence of esophageal dysmotility on manometry.
     Oral Oncol. 2025;162:107219.
     

     >> Share

     
     
176. YANG H, Sun P, Wang Y, Wang X, et al
     Mitoxantrone hydrochloride liposome injection for the treatment of Recurrent/Metastatic head and neck squamous cell Carcinoma: A Multicenter, Open-label, Single-arm, phase 1b study.
     Oral Oncol. 2025;162:107211.
     

     >> Share

     
     
177. IQBAL MS, West N, Kovarik J, Jackson M, et al
     Effective, efficient palliative radiotherapy for advanced head and neck cancer: Real world data using 25 Gy in 5 fractions.
     Oral Oncol. 2025;162:107214.
     

     >> Share

     
     
178. KHAN A, Pillay M, Bipath R, Msimang M, et al
     Evolution of testing for the diagnosis of human papillomavirus (HPV) status in head and neck squamous cell carcinoma: Where from and where to?
     Oral Oncol. 2025;162:107208.
     

     >> Share

     
     
179. MO Y, Wei Y, Liang L, Wu T, et al
     Clinical significance of post-chemoradiotherapy 2-[(18)F]FDG PET/CT response in locally advanced nasopharyngeal carcinoma: A real-world study.
     Oral Oncol. 2025;161:107160.
     

     >> Share

     
     
180. LOUBIERES C, Baudouin R, Circiu M, Couineau F, et al
     Functional and oncological outcomes of transoral laser versus robotic surgery in supraglottic squamous cell carcinoma.
     Oral Oncol. 2025;161:107178.
     

     >> Share

     
     
181. PERSHAD AR, Ferraro T, Shaver TB, Lee E, et al
     Pathologic responses and clinical outcomes with neoadjuvant doublet chemotherapy for newly diagnosed, surgically-resectable p16-positive oropharyngeal cancer.
     Oral Oncol. 2025;161:107139.
     

     >> Share

     
     
182. FENG ZK, Wu WB, Zou RC, Zhang JZ, et al
     Postradiotherapy nasopharyngeal necrosis with granulation mass: Insights from a multicentre study.
     Oral Oncol. 2025;161:107170.
     

     >> Share

     
     
183. LYU SI, Fretter C, Eckel HNC, Knipper K, et al
     High expression of H2AX/gamma-H2AX is associated with distinct biological pathway alterations and shorter survival in oropharyngeal squamous cell carcinoma.
     Oral Oncol. 2025;161:107171.
     

     >> Share

     
     
184. KWON JJ, Milner TD, Kurten C, Pang EH, et al
     Towards transcervical ultrasound-guided transoral robotic surgery.
     Oral Oncol. 2025;161:107167.
     

     >> Share

     
     
185. SUCHAN M, Wuerdemann N, Wagner S, Langer C, et al
     Histological and genetic criteria define a clinically relevant subgroup of HPV-positive oropharyngeal carcinoma.
     Oral Oncol. 2025;162:107209.
     

     >> Share

     
     January 2025
186. WENGER TA, Gao J, Nurimba M, Phung PG, et al
     Palliative care utilization among head and neck cancer patients: A population-based analysis.
     Oral Oncol. 2025;162:107205.
     

     >> Share

     
     
187. CHEN L, Fang R, Cai Z, Huang B, et al
     CD271(high) cancer stem cells regulate macrophage polarization in head and neck squamous cell carcinoma.
     Oral Oncol. 2025;162:107181.
     

     >> Share

     
     
188. YIN Z, Zhao H, Zhu C, Fang J, et al
     Comment on: Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy.
     Oral Oncol. 2025;161:107195.
     

     >> Share

     
     
189. JIANG H, Zhou L, Zhao T, Zou G, et al
     Anaplastic thyroid carcinoma in a 43-year-old female confirmed by metastatic lymph node pathology: A case report.
     Oral Oncol. 2025;161:107192.
     

     >> Share

     
     
190. JIANG H, Zhou L, Zou G, Zhang H, et al
     Synchronous papillary and medullary thyroid carcinoma with distinct genetic mutations: A case report.
     Oral Oncol. 2025;161:107191.
     

     >> Share

     
     
191. LI MH, Hu YJ, Shan HM, Gao XL, et al
     The role of lymph node level ratio in predicting prognosis and the benefits of postoperative radiotherapy in patients with pathological N1 stage head and neck squamous cell carcinoma.
     Oral Oncol. 2025;161:107193.
     

     >> Share

     
     
192. HUTTINGER ZM, Gogineni E, Baliga S, Blakaj DM, et al
     Circulating tumor DNA determines induction chemotherapy response in HPV associated oropharyngeal squamous cell carcinoma: A pilot study.
     Oral Oncol. 2025;161:107179.
     

     >> Share

     
     
193. TOPKAN E, Somay E, Selek U
     Commentary on "Induction chemotherapy for locally advanced nasopharyngeal carcinoma: Efficacy and safety of the TPC regimen compared to GP and TPF".
     Oral Oncol. 2025;161:107175.
     

     >> Share

     
     
194. SENYUREK S, Durankus NK, Selek U, Topkan E, et al
     Comment on "The effect of time from surgery to commencing adjuvant radiotherapy for patients with head and neck squamous cell carcinoma".
     Oral Oncol. 2025;161:107177.
     

     >> Share

     
     
195. GIUNCO S, Del Mistro A, Morello M, Lidonnici J, et al
     From infection to immortality: The role of HPV and telomerase in head and neck cancer.
     Oral Oncol. 2025;161:107169.
     

     >> Share

     
     
196. HANNA GJ, Zheng D, Gao W, Hair GM, et al
     PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S.
     Oral Oncol. 2025;161:107146.
     

     >> Share

     
     
197. XU S, He J, Liu Z, Pei Y, et al
     Immune-related adverse events as prognostic biomarkers in recurrent or metastatic nasopharyngeal carcinoma receiving PD-L1 inhibitor: A post-hoc analysis of the multicenter, single-arm, phase 2 study.
     Oral Oncol. 2025;161:107161.
     

     >> Share

     
     December 2024
198. KAOREY N, Dickinson K, Agnihotram VR, Zeitouni A, et al
     The role of ctDNA from liquid biopsy in predicting survival outcomes in HPV-negative head and neck cancer: A meta-analysis.
     Oral Oncol. 2024;161:107148.
     

     >> Share

     
     
199. LIU Y, Fu N, Liu H, Su S, et al
     Corrigendum to "Risk factors of lymph node metastasis in the diffuse sclerosing variant of papillary thyroid carcinoma compared with conventional papillary thyroidcarcinoma in pediatric populations" [160 (2025) 107120/Article:OO_107120].
     Oral Oncol. 2024 Dec 30:107135. doi: 10.1016/j.oraloncology.2024.107135.
     

     >> Share

     
     
200. DIETRICH N, Watson E, Tadic T, Martino R, et al
     Development of a prediction model for tube feeding dependence in HPV-associated oropharyngeal cancer patients undergoing chemoradiotherapy.
     Oral Oncol. 2024;161:107132.
     

     >> Share

     
     
201. FANG Q, Yuan J, Zhang X, Dai L, et al
     Omitting elective neck dissection in cT1/2N0 oral squamous cell carcinoma with sentinel lymph node metastasis: A prospective study.
     Oral Oncol. 2024;161:107149.
     

     >> Share

     
     
202. PRICE JM, Garcez K, Hughes C, Lee LW, et al
     The effect of time from surgery to commencing adjuvant radiotherapy for patients with head and neck squamous cell carcinoma.
     Oral Oncol. 2024;161:107138.
     

     >> Share

     
     
203. STRUCKMEIER AK, Gosau M, Smeets R
     Immunotherapeutic strategies beyond the PD-1/PD-L1 pathway in head and neck squamous cell carcinoma - A scoping review on current developments in agents targeting TIM-3, TIGIT, LAG-3, and VISTA.
     Oral Oncol. 2024;161:107145.
     

     >> Share

     
     
204. MEGWALU UC, Ma Y, Divi V
     Association of race and ethnicity with quality of care among head and neck cancer patients in California.
     Oral Oncol. 2024;161:107144.
     

     >> Share

     
     
205. PACE GM, Costantino A, De Virgilio A
     Comment on "Surgical, functional, and oncological outcomes of transoral robotic surgery for cT1-T3 supraglottic laryngeal cancers: A systematic review".
     Oral Oncol. 2024;161:107142.
     

     >> Share

     
     
206. YU ST, Huang D, Xiong C, Xie R, et al
     Selperctinib as neoadjuvant therapy for RET-altered papillary thyroid carcinoma: Two case reports.
     Oral Oncol. 2024;161:107140.
     

     >> Share

     
     
207. ALMEIDA ND, Yu H, Iovoli AJ, Fang M, et al
     Prophylactic gastrostomy tube during chemoradiation for head and neck cancer decreases weight loss but increases rate of tube use beyond six months.
     Oral Oncol. 2024;160:107136.
     

     >> Share

     
     
208. DA MOTA SANTANA LA, Dos Santos Barreto M, Santos GA, Gopalsamy RG, et al
     Comment on "Time to treatment for head and neck cancer patients decreased during the early phase of the COVID-19 pandemic".
     Oral Oncol. 2024;160:107134.
     

     >> Share

     
     
209. PRACHA SH, Shrestha S, Ryan N, Upadhaya P, et al
     Targeting macrophage migration inhibitory factor to inhibit T cell immunosuppression in the tumor microenvironment and improve cancer outcomes in head and neck squamous cell carcinoma.
     Oral Oncol. 2024;160:107126.
     

     >> Share

     
     
210. LI H, Lou L, Du J, Li M, et al
     Multimodal profiling uncovers tertiary lymphoid structures as a critical determinant of immunotherapy response and prognosis in nasopharyngeal carcinoma.
     Oral Oncol. 2024;160:107129.
     

     >> Share

     
     
211. SANKAR GANESH P, Naseef Pathoor N, Kanna Gopal R
     Letter to the editor regarding, "Impact of post-operative transoral robotic surgery hemorrhage on adjuvant treatment delays in patients with oropharyngeal squamous cell carcinoma".
     Oral Oncol. 2024;159:107091.
     

     >> Share

     
     
212. BALAJI H, Aithal VU, Varghese JJ, Devaraja K, et al
     Agreement between patient-reported and clinician-rated speech and swallowing outcomes - Understanding the trend in post-operative oral cavity cancer patients.
     Oral Oncol. 2024;159:107068.
     

     >> Share

     
     
213. BALAGURU L, Hanubal KS, Galochkina Z, Lee JH, et al
     Surgical and functional outcomes after salvage oropharyngectomy.
     Oral Oncol. 2024;159:107050.
     

     >> Share

     
     
214. KORIC A, Chang CP, Hu S, Snyder J, et al
     Oral health-related quality of life among oropharyngeal cancer survivors.
     Oral Oncol. 2024;159:107062.
     

     >> Share

     
     
215. BOZKURT G, Turri Zanoni M, Ferrari M, Ioppi A, et al
     Salvage surgery in nasopharyngeal Cancer: Unraveling the efficacy of transnasal endoscopic nasopharyngectomy for advanced stage recurrent tumors.
     Oral Oncol. 2024;159:107048.
     

     >> Share

     
     
216. DANIELS KE, Awad DR, Liu SX, Mocharnuk J, et al
     Impact of post-operative transoral robotic surgery hemorrhage on adjuvant treatment delays in patients with oropharyngeal squamous cell carcinoma.
     Oral Oncol. 2024;159:107031.
     

     >> Share

     
     
217. GREEN L, McDowell L, Ip F, Tapia M, et al
     Early return to work is possible after transoral robotic surgery (TORS) in carefully selected patients with oropharyngeal squamous cell carcinoma.
     Oral Oncol. 2024;159:107032.
     

     >> Share

     
     
218. LU YT, Lin CW, Su SC, Ho YT, et al
     L48H37, a curcumin analog, suppresses matrix metalloproteinase-9 expression and activity to hamper nasopharyngeal cancer cell migration.
     Oral Oncol. 2024;159:107038.
     

     >> Share

     
     
219. STAIBANO P, Au M, Xie M, Gupta MK, et al
     Return to work and self-reported swallowing following transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma: A retrospective cohort study.
     Oral Oncol. 2024;159:107033.
     

     >> Share

     
     
220. MORTAJA S, Chiumenti FA, Kalaskar DM, Dwivedi RC, et al
     Surgical complications and functional outcomes of 3191 jejunal free flaps used for reconstruction of circumferential defects following head and neck cancer resections: A systematic review.
     Oral Oncol. 2024;160:107130.
     

     >> Share

     
     November 2024
221. MARRET G, Lamy C, Vacher S, Cabel L, et al
     Deciphering molecular relapse and intra-tumor heterogeneity in non-metastatic resectable head and neck squamous cell carcinoma using circulating tumor DNA.
     Oral Oncol. 2024;160:107111.
     

     >> Share

     
     
222. JEYARAJ G
     Letter to the editor, "Loss of MACROD2 drives radioresistance but not cisplatin resistance in HPV-positive head and neck cancer.".
     Oral Oncol. 2024;160:107092.
     

     >> Share

     
     
223. LIU Y, Fu N, Liu H, Su S, et al
     Risk factors of lymph node metastasis in the diffuse sclerosing variant of papillary thyroid carcinoma compared with conventional papillary thyroidcarcinoma in pediatric populations.
     Oral Oncol. 2024;160:107120.
     

     >> Share

     
     
224. YAN C, Wang R, Zhang C, Lin G, et al
     Induction chemotherapy for locally advanced nasopharyngeal carcinoma: Efficacy and safety of the TPC regimen compared to GP and TPF.
     Oral Oncol. 2024;160:107119.
     

     >> Share

     
     
225. VON WITZLEBEN A, Grages A, Thomas J, Ezic J, et al
     Immune checkpoint expression on tumor-infiltrating lymphocytes (TIL) is dependent on HPV status in oropharyngeal carcinoma (OPSCC) - A single-cell RNA sequencing analysis.
     Oral Oncol. 2024;159:107107.
     

     >> Share

     
     
226. LI S, Zhao T, Liu N, Li Y, et al
     Global research on oral cancer: A bibliometric analysis based on 82 highly cited publications from 2014 to 2024.
     Oral Oncol. 2024;159:107094.
     

     >> Share

     
     
227. YANG B, Dai X, Li Z, Wu Z, et al
     Noninvasive surface-enhanced Raman spectroscopy outperforms combined positive score in predicting sensitivity to neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
     Oral Oncol. 2024;159:107105.
     

     >> Share

     
     
228. RENGASAMY G, Priya Veeraraghavan V
     Using salivary DNA methylation to predict aging, cell changes, and protein levels for assessing oral mucositis severity and survival in head and neck cancer patients.
     Oral Oncol. 2024;159:107086.
     

     >> Share

     
     
229. LEE YC, Hsin LJ, Lin WN, Fang TJ, et al
     Robot-assisted versus conventional neck dissection in head and neck cancers: A systematic review and meta-analysis.
     Oral Oncol. 2024;159:107101.
     

     >> Share

     
     
230. MORGENTHALER J, Trommer M, Khor R, Wada M, et al
     Can we safely de-escalate HPV(+) oropharyngeal cancers? - A review of current practices and novel approaches.
     Oral Oncol. 2024;159:107089.
     

     >> Share

     
     
231. LENNON SILVA CUNHA J
     In reply to "Risk of cardiovascular disease among head and neck cancer survivors: A population-based matched cohort study".
     Oral Oncol. 2024;159:107096.
     

     >> Share

     
     
232. TOPKAN E, Somay E, Ozturk D, Selek U, et al
     Commentary on "Effect analysis of 847 nasopharyngeal carcinoma cases treated with intensity modulated radiation: Experience and suggestions".
     Oral Oncol. 2024;159:107099.
     

     >> Share

     
     
233. SHANG K, Li T, Chen Y, Luo X, et al
     Gemcitabine plus cisplatin versus docetaxel plus cisplatin and fluorouracil induction chemotherapy combined with locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A single center prospective phase II clinical trial.
     Oral Oncol. 2024;159:107087.
     

     >> Share

     
     
234. COSTANTINO A, Haughey B, Alamoudi U, Magnuson JS, et al
     Challenges in treating oropharyngeal cancer in the elderly: The role of transoral surgery.
     Oral Oncol. 2024;158:106996.
     

     >> Share

     
     
235. SOLARZ P, Mackiewicz-Nartowicz H, Sinkiewicz A, Burduk P, et al
     Results of CO2 laser surgery in laryngeal papillomatosis.
     Oral Oncol. 2024;158:107004.
     

     >> Share

     
     
236. ASHIQUE S, Houshyari M, Islam A, Pal R, et al
     The role of microbiota in nasopharyngeal cancer: Where do we stand?
     Oral Oncol. 2024;158:106982.
     

     >> Share

     
     
237. DE SENA COSTA DE OLIVEIRA D, Cunha JLS
     Comment on: Salivary DNA methylation derived estimates of biological aging, cellular frequency, and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients.
     Oral Oncol. 2024;159:107097.
     

     >> Share

     
     
238. HIMANI
     Letter to the editor: Burden of oral cancer and associated risk factors at national and state levels: A systematic analysis from the global burden of disease in India, 1990-2021.
     Oral Oncol. 2024;159:107093.
     

     >> Share

     
     October 2024
239. MUTHAMIZH S, Balachandran S, Dilipan E
     Opinion on "Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma".
     Oral Oncol. 2024;159:107095.
     

     >> Share

     
     
240. LEHYANTI J, Even C, Fessart E, Wagner-Ballon C, et al
     Management of oligometastatic head and neck squamous cell carcinoma: A systematic review.
     Oral Oncol. 2024;159:107085.
     

     >> Share

     
     
241. VILLARME A, Ebran N, Pace-Loscos T, Schiappa R, et al
     Prognostic impact of intra tumoral HPV-16 viral load in oropharyngeal squamous cell carcinomas.
     Oral Oncol. 2024;159:107082.
     

     >> Share

     
     
242. KARAMCHANDANI S, Sahovaler A, Crosbie-Jones E, McGurk M, et al
     Incidence and predictive factors for positive non-sentinel lymph nodes in completion neck dissection following a positive sentinel node biopsy in early oral cancer.
     Oral Oncol. 2024;159:107081.
     

     >> Share

     
     
243. LI D, Lopez A, Shrivastava N, Chan W, et al
     Comprehensive functional evaluation of head and neck squamous cell carcinoma with BH3-profiling demonstrates apoptotic competency and therapeutic efficacy of BH3-mimetics.
     Oral Oncol. 2024;159:107069.
     

     >> Share

     
     
244. WU WB, Xia L, Feng ZK, Liang JL, et al
     Characteristics and treatment of epistaxis in nasopharyngeal carcinoma.
     Oral Oncol. 2024;159:107071.
     

     >> Share

     
     
245. ZANG Y, Lu Y, Yu J, Dong Q, et al
     FOXP3 inhibits proliferation and migration by competitively inhibiting YAP1 in nasopharyngeal carcinoma.
     Oral Oncol. 2024;159:107066.
     

     >> Share

     
     
246. GARSET-ZAMANI M, Lomholt AF, Charabi BW, Norling R, et al
     Surgeon-performed intraoperative transoral ultrasound improves the detection of human papillomavirus-positive head and neck cancers of unknown primary.
     Oral Oncol. 2024;159:107073.
     

     >> Share

     
     
247. LIU C, Zhao H, Lu Y, Xia Y, et al
     Nomograms to predict occult contralateral central lymph node metastases in unilateral papillary thyroid carcinoma with ipsilateral clinical lymph node metastasis.
     Oral Oncol. 2024;159:107051.
     

     >> Share

     
     
248. SONG Y, Zhang Y, Bai Y, Wang T, et al
     Combination kinase inhibitors and immunotherapy for unresectable anaplastic thyroid carcinoma: A retrospective single-center study.
     Oral Oncol. 2024;159:107067.
     

     >> Share

     
     
249. AWEEDA M, Richard K, Arnaud EH, Divi V, et al
     Factors influencing lymph node yield in head and neck squamous cell carcinoma: A scoping review.
     Oral Oncol. 2024;159:107070.
     

     >> Share

     
     
250. HE SQ, Liu GY, Yu YH, Wang L, et al
     Establishing M1 subdivision for de novo nasopharyngeal carcinoma patients receiving immuno-chemotherapy: A multicenter, retrospective cohort study.
     Oral Oncol. 2024;159:107074.
     

     >> Share

     
     
251. LEE RH, Evans C, Alqasieer Y, Knott PD, et al
     Bite me: Can active biting during trismus therapy improve mouth opening in head and neck cancer patients?
     Oral Oncol. 2024;159:107064.
     

     >> Share

     
     
252. ZHAO BY, Hirayama S, Goss D, Zhao Y, et al
     Human papillomavirus-associated nasopharyngeal carcinoma: A systematic review and meta-analysis.
     Oral Oncol. 2024;159:107057.
     

     >> Share

     
     
253. TANG WZ, Xu WZ, Liu TH
     Exploring the potential of gemcitabine, capecitabine, and tislelizumab after anti-PD-1 treatment in nasopharyngeal carcinoma.
     Oral Oncol. 2024;159:107065.
     

     >> Share

     
     
254. YACOUB I, Qian JY, Nashed K, Youssef M, et al
     Radiation techniques and advancements in nasopharyngeal carcinoma.
     Oral Oncol. 2024;159:107060.
     

     >> Share

     
     
255. GAUDIOSO P, Contro G, Taboni S, Costantino P, et al
     Intraoperative surgical navigation as a precision medicine tool in sinonasal and craniofacial oncologic surgery.
     Oral Oncol. 2024;157:106979.
     

     >> Share

     
     
256. DAWSON A, Karimi AH, Shaikh MH, Gazala W, et al
     Loss of MACROD2 drives radioresistance but not cisplatin resistance in HPV-positive head and neck cancer.
     Oral Oncol. 2024;159:107061.
     

     >> Share

     
     
257. AKASHANAND, Zahiruddin QS, Jena D, Ballal S, et al
     Burden of oral cancer and associated risk factors at national and state levels: A systematic analysis from the global burden of disease in India, 1990-2021.
     Oral Oncol. 2024;159:107063.
     

     >> Share

     
     September 2024
258. LECHIEN JR
     Surgical, Functional, and oncological outcomes of transoral robotic surgery for cT1-T3 supraglottic laryngeal Cancers: A systematic review.
     Oral Oncol. 2024;159:107047.
     

     >> Share

     
     
259. KEEFE K, McCrary HC, Wei M, Mark B, et al
     Risk of cardiovascular disease among head and neck cancer survivors: A population-based matched cohort study.
     Oral Oncol. 2024;159:107041.
     

     >> Share

     
     
260. DHARSHINI RAJATHIRAJAN S
     Commentary on "Salivary DNA methylation derived estimates of biological aging, cellular frequency and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients".
     Oral Oncol. 2024;159:107053.
     

     >> Share

     
     
261. LYU W, Gong J, Zhu L, Xu T, et al
     MR radiomics unveils neoadjuvant chemo-responsiveness with insights into selective treatment de-intensification in HPV-positive oropharyngeal carcinoma.
     Oral Oncol. 2024;159:107049.
     

     >> Share

     
     
262. PRITHVIRAJ
     Comment on "Sexual Health, sexuality and sexual intimacy in patients with head and neck cancer".
     Oral Oncol. 2024;159:107054.
     

     >> Share

     
     
263. DINESHKUMAR R
     Letter to the editor: Risk factors associated with ototoxicity in long-term survivors of nasopharyngeal carcinoma.
     Oral Oncol. 2024;159:107052.
     

     >> Share

     
     
264. VALCENKO A, Zwick A, Schneider L, Linxweiler M, et al
     The tumor cell killing capacity of head and neck cancer patient-derived neutrophils depends on tumor stage, gender and the antibody isotype.
     Oral Oncol. 2024;159:107042.
     

     >> Share

     
     
265. MIN Y, Liu X, Wei Z, Song G, et al
     Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study.
     Oral Oncol. 2024;159:107028.
     

     >> Share

     
     
266. RENGASAMY G, Priya Veeraraghavan V
     Comment on "The prognostic value of image-identified extranodal extension in laryngeal and hypopharyngeal carcinoma following definitive (chemo-) radiotherapy".
     Oral Oncol. 2024;159:107035.
     

     >> Share

     
     
267. DHARSHINI RAJATHIRAJAN S
     Commentary on "Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression.".
     Oral Oncol. 2024;159:107037.
     

     >> Share

     
     
268. DHARSHINI RAJATHIRAJAN S
     Commentary on "Predictive value of CXCL1(+)_FAP(+) phenotype in CAFs for distant metastasis and its correlation with PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma patients".
     Oral Oncol. 2024;159:107036.
     

     >> Share

     
     
269. VERSCHOOR CP, Santi SA, Singh R, Tharmalingam S, et al
     Salivary DNA methylation derived estimates of biological aging, cellular frequency and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients.
     Oral Oncol. 2024;159:107030.
     

     >> Share

     
     
270. PAKA LUBAMBA G, Hua Y, Bao M, Zhang G, et al
     Variant of internal jugular vein reconstruction in bilateral radical neck dissection.
     Oral Oncol. 2024;159:107015.
     

     >> Share

     
     
271. WANG A, Xia H, Li J, Diao P, et al
     Development of a novel prognostic signature derived from super-enhancer-associated gene by machine learning in head and neck squamous cell carcinoma.
     Oral Oncol. 2024;159:107016.
     

     >> Share

     
     
272. PRITHVIRAJ T
     Commentary on "Tumor Habitat-Based MRI features assessing early response in locally advanced nasopharyngeal carcinoma".
     Oral Oncol. 2024;159:107018.
     

     >> Share

     
     
273. XIAOYU J, Baihong P, Yaozhen L, Shen C, et al
     Preoperative protective stenting of the carotid artery in severe complex head and neck cancer resection.
     Oral Oncol. 2024;158:107012.
     

     >> Share

     
     
274. PAYNE K, Suriyanarayanan H, Brooks J, Mehanna H, et al
     Exploring the impact of intra-tumoural heterogeneity on liquid biopsy cell-free DNA methylation and copy number in head and neck squamous cell carcinoma.
     Oral Oncol. 2024;158:107011.
     

     >> Share

     
     
275. ZHANG X, Zheng W, Huang S, Li H, et al
     Xerostomia prediction in patients with nasopharyngeal carcinoma during radiotherapy using segmental dose distribution in dosiomics and radiomics models.
     Oral Oncol. 2024;158:107000.
     

     >> Share

     
     
276. CHEN J, Cheng H, Liang Y, Lin J, et al
     The efficacy of adjuvant chemotherapy in patients with different midpoint-radiotherapy Epstein-Barr virus DNA plasma loads.
     Oral Oncol. 2024;156:106938.
     

     >> Share

     
     August 2024
277. LECHIEN JR, Hans S
     Survival, Surgical, and functional outcomes of transoral laser microsurgery for cT1-T3 supraglottic laryngeal Cancers: A systematic review.
     Oral Oncol. 2024;158:107009.
     

     >> Share

     
     
278. ZHAO J, Ruan X, Wei S, Zheng X, et al
     The first report of bilateral parapharyngeal lymph node metastasis from papillary thyroid carcinoma: A case report.
     Oral Oncol. 2024;158:107006.
     

     >> Share

     
     
279. YIN WJ, Mao W, Yang F, Wang MY, et al
     Effect analysis of 847 nasopharyngeal carcinoma cases treated with intensity modulated radiation: Experience and suggestions.
     Oral Oncol. 2024;158:107001.
     

     >> Share

     
     
280. GE Y, Liu H, Huang W, Zhu H, et al
     Immunoinhibitory effects of hypoxia-driven reprogramming of EGR1(hi) and EGR3 positive B cells in the nasopharyngeal carcinoma microenvironment.
     Oral Oncol. 2024;158:106999.
     

     >> Share

     
     
281. T P
     Commentary on "Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/mHNSCC)".
     Oral Oncol. 2024;158:107010.
     

     >> Share

     
     
282. ZHOU X, Shao T, Jia H, Hou L, et al
     Current state, challenges, and future perspective of adaptive radiotherapy: A narrative review of nasopharyngeal carcinoma.
     Oral Oncol. 2024;158:107008.
     

     >> Share

     
     
283. PRASAD M
     DNA Methylation Mediated Epigenetic Silencing of PD-1 and PD-L1: Therapeutic Implications in Oral Cancer.
     Oral Oncol. 2024 Aug 23:106995. doi: 10.1016/j.oraloncology.2024.106995.
     

     >> Share

     
     
284. KNAP RABJERG H, Grau Eriksen J, Soby S
     Impact of antibiotics on PD-1 inhibition in recurrent/metastatic head and neck squamous cell carcinoma.
     Oral Oncol. 2024;158:107003.
     

     >> Share

     
     
285. DU F, Shao K, Yang Y, Bai X, et al
     Comparative dosimetric analysis of normal brain tissue in patients with Nasopharyngeal carcinoma at different stages after radiation therapy.
     Oral Oncol. 2024;158:106998.
     

     >> Share

     
     
286. ALSHEIKH S, Su J, O'Sullivan B, Ringash J, et al
     The prognostic value of image-identified extranodal extension in laryngeal and hypopharyngeal carcinoma following definitive (chemo-)radiotherapy.
     Oral Oncol. 2024;158:107007.
     

     >> Share

     
     
287. SUN L, Cohen RB, Dimitrios Colevas A
     Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC).
     Oral Oncol. 2024;158:106997.
     

     >> Share

     
     
288. HANNA GJ, Jabalee J, Lukens JN, Sun L, et al
     Circulating tumor tissue modified viral (TTMV)-HPV DNA in Recurrent, metastatic HPV-driven oropharyngeal cancer.
     Oral Oncol. 2024;158:107002.
     

     >> Share

     
     
289. YUAN J, Wu M, Qiu L, Xu W, et al
     Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma.
     Oral Oncol. 2024;158:106980.
     

     >> Share

     
     
290. YANG R, Li R, Niu X, Zhao Y, et al
     Gemcitabine, capecitabine, and tislelizumab in recurrent/metastatic nasopharyngeal carcinoma following prior anti-PD-1 therapy failure: A retrospective study.
     Oral Oncol. 2024;158:106981.
     

     >> Share

     
     
291. HUSSEIN NI, Molina AH, Sunga GM, Amit M, et al
     Localized intratumoral delivery of immunomodulators for oral cancer and oral potentially malignant disorders.
     Oral Oncol. 2024;158:106986.
     

     >> Share

     
     
292. PAN GS, Sun XM, Kong FF, Wang JZ, et al
     Delta magnetic resonance imaging radiomics features?based nomogram predicts long?term efficacy after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
     Oral Oncol. 2024;157:106987.
     

     >> Share

     
     
293. QIN G, Liao X, Zhang B, Su Y, et al
     An individualized immune prognostic signature in nasopharyngeal carcinoma.
     Oral Oncol. 2024;157:106985.
     

     >> Share

     
     
294. TAMIOLAKIS P, Shah A, Dawson R, Ramasamy S, et al
     HPV- associated sinonasal squamous cell carcinoma with FGFR3::TACC3 fusion. A rare case report.
     Oral Oncol. 2024;157:106983.
     

     >> Share

     
     
295. SHIMIZU H, Kodaira T, Kiyota N, Hayashi R, et al
     Incidence and risk factors associated with the development of hypothyroidism after postoperative chemoradiotherapy for head and neck cancer patients with high-risk features: Supplementary analysis of JCOG1008.
     Oral Oncol. 2024;157:106976.
     

     >> Share

     
     
296. SANKAR S
     Letter to editor regarding "Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression".
     Oral Oncol. 2024;157:106977.
     

     >> Share

     
     
297. SCHAEFFERS AWMA, Scholten HA, van Beers MA, Meussen BW, et al
     The effect of skeletal muscle mass on dose-limiting toxicities during (chemo)radiotherapy in patients with head and neck cancer: A systematic review and meta-analysis.
     Oral Oncol. 2024;157:106978.
     

     >> Share

     
     July 2024
298. MCDOWELL L, Gough K, White I, Corry J, et al
     Sexual Health, sexuality and sexual intimacy in patients with head and neck cancer - A narrative review.
     Oral Oncol. 2024;157:106975.
     

     >> Share

     
     
299. DAS S, Ghosh Laskar S, V Kane S, D'Cruz AK, et al
     Adjuvant therapy for intermediate risk factors in oral cancer: Can we reach a consensus?
     Oral Oncol. 2024;157:106972.
     

     >> Share

     
     
300. JEYARAJ G
     Letter to the editor, "Clinical benefits of combining oral cytotoxic chemotherapeutic agents with radiotherapy in patients with T2N0 glottic squamous cell carcinoma based on the reports of the head and neck Cancer Registry of Japan.".
     Oral Oncol. 2024;157:106974.
     

     >> Share

     
     
301. JEYARAJ G
     Letter to the editor, "Mutation detection in saliva from oral cancer patients".
     Oral Oncol. 2024;157:106929.
     

     >> Share

     
     
302. GANESH PS, Pathoor NN, Gopal RK
     Letter to the editor regarding "Induction chemotherapy regimes in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: A network meta-analysis and cost-effectiveness analysis.
     Oral Oncol. 2024;157:106954.
     

     >> Share

     
     
303. LORINI L, Zigliani G, Morbini P, Salviato E, et al
     Expression of PDL-1 between primary and recurrent/metastatic head and neck squamous cell carcinoma: A bi-institutional retrospective concordance analysis (CONCORDL-1 study).
     Oral Oncol. 2024;157:106950.
     

     >> Share

     
     
304. JEYACHANDRAN S
     Comment on, "Characterization of oral microbiota in HPV and non-HPV head and neck squamous cell carcinoma and its association with patient outcomes".
     Oral Oncol. 2024;157:106973.
     

     >> Share

     
     
305. SURESH S
     Comment on: An algorithm for standardization of tumor infiltrating lymphocyte evaluation in head and neck cancers.
     Oral Oncol. 2024;157:106959.
     

     >> Share

     
     
306. WEN YF, Huang WJ, Chen XL, Cai HT, et al
     Predictive value of CXCL1(+)_FAP(+) phenotype in CAFs for distant metastasis and its correlation with PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma patients.
     Oral Oncol. 2024;157:106963.
     

     >> Share

     
     
307. ICHISAKA T, Sano D, Kijima N, Kawakita D, et al
     Clinical benefits of combining oral cytotoxic chemotherapeutic agents with radiotherapy in patients with T2N0 glottic squamous cell carcinoma based on the reports of the Head and Neck Cancer Registry of Japan.
     Oral Oncol. 2024;157:106942.
     

     >> Share

     
     
308. TINO R, Roach MA, Fuentes GD, Agrawal A, et al
     Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy.
     Oral Oncol. 2024;157:106944.
     

     >> Share

     
     
309. LIM CY, Ng GWY, Goh CK, Lee MKC, et al
     Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression.
     Oral Oncol. 2024;157:106941.
     

     >> Share

     
     
310. SHANMUGAM G
     Letter to the editor, "The prognostic value of pretreatment (18)F-FDG PET-CT parameters with peripheral blood markers in patients with de novo metastatic nasopharyngeal carcinoma.".
     Oral Oncol. 2024;157:106951.
     

     >> Share

     
     
311. MEIVELU MOOVENDHAN
     "Letter to the Editor: Next-Generation sequencing (NGS) profiling of matched tumor and Circulating Tumor DNA (ctDNA) in Head and Neck Squamous Cell Carcinoma (HNSCC)".
     Oral Oncol. 2024;157:106940.
     

     >> Share

     
     
312. ZENGA J, Himburg HA, Wong SJ, Kearl T, et al
     In silico identification of public neo-antigens in head and neck Cancer for T cell receptor Engineering: Targeting PI3KCA and TP53 missense mutations.
     Oral Oncol. 2024 Jul 14:106947. doi: 10.1016/j.oraloncology.2024.106947.
     

     >> Share

     
     
313. DHARMALINGAM JOTHINATHAN MK
     Letter to the Editor, "Immunochemotherapy alone or immunochemotherapy plus subsequent locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma".
     Oral Oncol. 2024;156:106948.
     

     >> Share

     
     
314. SHANMUGAM G
     Commentary on, "Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma.".
     Oral Oncol. 2024;156:106952.
     

     >> Share

     
     
315. PIYARATHNE NS, Liyanage SN, Rasnayaka RMSGK, Hettiarachchi PVKS, et al
     A comprehensive dataset of annotated oral cavity images for diagnosis of oral cancer and oral potentially malignant disorders.
     Oral Oncol. 2024;156:106946.
     

     >> Share

     
     
316. MAHDI AGM
     Knowledge, and attitude of medical students about role of human papilloma virus, and vaccine in head and neck cancer.
     Oral Oncol. 2024;156:106939.
     

     >> Share

     
     
317. SHANMUGAM G
     Letter to the editor, "Letter to the editor, "Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study.".
     Oral Oncol. 2024;156:106935.
     

     >> Share

     
     
318. ARUMUGANAINAR D, Sekaran S
     Correspondence on "Global burdens of nasopharyngeal carcinoma in children and young adults: Trends and predictions to 2040".
     Oral Oncol. 2024;156:106933.
     

     >> Share

     
     
319. GU LW, Zhang X, Zhang J, Xiao BB, et al
     The prognostic value of pretreatment (18)F-FDG PET-CT parameters with peripheral blood markers in patients with de novo metastatic nasopharyngeal carcinoma.
     Oral Oncol. 2024;156:106928.
     

     >> Share

     
     
320. SURESH S
     Commentary on 'Mutation detection in saliva from oral cancer patients'.
     Oral Oncol. 2024;156:106937.
     

     >> Share

     
     
321. KASIRAJAN H, Rengasamy G, Priya Veeraraghavan V
     Comment on the "Quality of life in 583 head and neck cancer survivors assessed with the FACE-Q head and neck cancer module".
     Oral Oncol. 2024;156:106934.
     

     >> Share

     
     
322. KANNAN R
     Comments on: Human Papilloma Virus vaccine and prevention of head and neck cancer, what is the current evidence?
     Oral Oncol. 2024;156:106936.
     

     >> Share

     
     
323. DAUNGSUPAWONG H, Wiwanitkit V
     Letter to the Editor on "Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance".
     Oral Oncol. 2024;156:106930.
     

     >> Share

     
     
324. LIOKATIS P, Liokati I, Obermeier K, Smolka W, et al
     Prognostic role of lymph node micrometastasis in oral and oropharyngeal cancer: A systematic review.
     Oral Oncol. 2024;154:106808.
     

     >> Share

     
     
325. CHEN AM
     Translational risk-adapted approaches to de-escalated radiation for human papillomavirus-positive oropharyngeal cancer: Past, present, and future.
     Oral Oncol. 2024;154:106850.
     

     >> Share

     
     
326. SATHISHKUMAR K
     Letter to the editor "risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial ".
     Oral Oncol. 2024;156:106931.
     

     >> Share

     
     
327. HARIDEVAMUTHU B
     Letter to the Editor: "Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell Carcinoma".
     Oral Oncol. 2024;156:106913.
     

     >> Share

     
     June 2024
328. BENJAMIN WJ, Feng AL, Heft Neal M, Bellile E, et al
     Utility of bioselection with neoadjuvant chemotherapy for organ preservation in patients with T4 laryngeal cancer.
     Oral Oncol. 2024;156:106917.
     

     >> Share

     
     
329. ZHAO X, Zhou Y, Peng G, Wen L, et al
     Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma.
     Oral Oncol. 2024;156:106918.
     

     >> Share

     
     
330. SARAVANAN M, Singh Carmelin D, Mohanprasanth A, Arockiaraj J, et al
     Comment on "Oral microbiome and risk of incident head and neck cancer: A nested case-control study".
     Oral Oncol. 2024;156:106911.
     

     >> Share

     
     
331. POONGAVANAM SS, Behera A, Dharmalingam Jothinathan MK
     Letter to the editor, "Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer".
     Oral Oncol. 2024;156:106912.
     

     >> Share

     
     
332. JEYARAJ G
     Letter to the editor, "Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer".
     Oral Oncol. 2024;156:106906.
     

     >> Share

     
     
333. DONG S, Bei W, Lin L, Jiang Y, et al
     Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study.
     Oral Oncol. 2024;156:106908.
     

     >> Share

     
     
334. JEYARAJ G
     Transformative impact of 3D-Printed implants and Virtual surgical planning in oral cancer reconstruction.
     Oral Oncol. 2024;156:106896.
     

     >> Share

     
     
335. SHANMUGAM G
     Letter to the editor, "Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer.".
     Oral Oncol. 2024;156:106915.
     

     >> Share

     
     
336. BASTIEN AJ, Ng J, Cong I, Garcia J, et al
     Patient perceptions underlying ctDNA molecular surveillance for HPV(+) oropharyngeal squamous cell carcinoma.
     Oral Oncol. 2024;156:106894.
     

     >> Share

     
     
337. HARIDEVAMUTHU B
     Letter to the Editor: "Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral Cancer".
     Oral Oncol. 2024;155:106902.
     

     >> Share

     
     
338. MEIVELU MOOVENDHAN
     Letter to the editor, "Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma".
     Oral Oncol. 2024;155:106903.
     

     >> Share

     
     
339. PRASAD M, Sekar R, Murugan R
     Letter to editor on "Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer".
     Oral Oncol. 2024;155:106899.
     

     >> Share

     
     
340. SELVI POONGAVANAM S, Behera A, Kumar Dharmalingam Jothinathan M
     Letter to the Editor, "The predictive role of PD-L1 in head and neck Cancer: A systematic review and Meta-Analysis".
     Oral Oncol. 2024;155:106904.
     

     >> Share

     
     
341. TOPKAN E, Somay E, Bascil S, Selek U, et al
     Comment on prospective comparison of acute severe toxicities between smokers and non-smokers during radiotherapy for head and neck cancers.
     Oral Oncol. 2024;155:106898.
     

     >> Share

     
     
342. HARIDEVAMUTHU B
     Genomic instability in HPV-positive oropharyngeal squamous cell carcinoma: The role of integration sites in treatment response.
     Oral Oncol. 2024;155:106895.
     

     >> Share

     
     
343. LEI S, Chen L, Ji P, Li K, et al
     Global burdens of nasopharyngeal carcinoma in children and young adults and predictions to 2040.
     Oral Oncol. 2024;155:106891.
     

     >> Share

     
     
344. DA MOTA SANTANA LA, Simoes JMD, Santos GA, Gopalsamy RG, et al
     Comment on "Association between COVID 19 exposure and expression of malignant pathological features in oral cancer: A retrospective cohort study".
     Oral Oncol. 2024;155:106877.
     

     >> Share

     
     
345. ROOF SA, Jabalee J, Rettig EM, Chennareddy S, et al
     Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance.
     Oral Oncol. 2024;155:106874.
     

     >> Share

     
     
346. FERRARI M, Mularoni F, Taboni S, Crosetti E, et al
     Corrigendum to "How reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? a multi-institutional study on 366 patients from the ARYFIX collaborative group" [Oral Oncol. 152C (2024) 106744].
     Oral Oncol. 2024 Jun 8:106887. doi: 10.1016/j.oraloncology.2024.106887.
     

     >> Share

     
     
347. PRASAD M, Murugan R
     Comment on "The circadian clock gene, BMAL1, promotes radiosensitization in nasopharyngeal carcinoma by inhibiting the epithelial-to-mesenchymal transition via the TGF-beta1/Smads/Snail1 axis".
     Oral Oncol. 2024;155:106890.
     

     >> Share

     
     
348. TASOULAS J, Adams GJ, Schrank TP, Agala CB, et al
     Time to treatment for head and neck cancer patients decreased during the early phase of the Covid-19 pandemic.
     Oral Oncol. 2024;155:106879.
     

     >> Share

     
     
349. DHARMALINGAM JOTHINATHAN MK
     Letter to the Editor, "How reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? A multi-institutional study on 366 patients from the ARYFIX collaborative group".
     Oral Oncol. 2024;155:106878.
     

     >> Share

     
     
350. BABU S, Krishnan M
     Human papillomavirus and oropharyngeal cancer in HNSCC: A growing concern.
     Oral Oncol. 2024;153:106824.
     

     >> Share

     
     
351. PACE GM, Costantino A, Festa BM, Spriano G, et al
     Oropharyngeal squamous cell carcinoma: Treatment (de-) intensification?
     Oral Oncol. 2024;153:106299.
     

     >> Share

     
     
352. LU HA, Wang YM, Chih Chen W, Wu CN, et al
     Post-irradiation dysbiosis in patients with nasopharyngeal carcinoma having received radiotherapy - A pilot study.
     Oral Oncol. 2024;154:106864.
     

     >> Share

     
     
353. KRC R, Mendes W, Molitoris J, Ferris M, et al
     Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer.
     Oral Oncol. 2024;154:106875.
     

     >> Share

     
     May 2024
354. XU W, Qiu L, Li F, Fei Y, et al
     Induction chemotherapy regimes in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: A network meta-analysis and cost-effectiveness analysis.
     Oral Oncol. 2024;154:106865.
     

     >> Share

     
     
355. IMAMURA Y, Kiyota N, Tahara M, Kodaira T, et al
     Risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial.
     Oral Oncol. 2024;154:106868.
     

     >> Share

     
     
356. PARK R, Li J, Slebos RJC, Chaudhary R, et al
     Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
     Oral Oncol. 2024;154:106866.
     

     >> Share

     
     
357. SARAVANAN M, Carmelin DS, Mohanprasanth A, Arockiaraj J, et al
     Comment on "Oral microbiome and risk of incident head and neck cancer: A nested case-control study".
     Oral Oncol. 2024;154:106858.
     

     >> Share

     
     
358. HESHAM A, David Kim D, Alshamrani Y, AlOtaibi F, et al
     The efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy in recurrent head and neck squamous cell carcinoma. Report of a case and review of the literature.
     Oral Oncol. 2024;154:106863.
     

     >> Share

     
     
359. ABBACI M, Villard A, Auperin A, Asmandar S, et al
     Ultra-fast confocal fluorescence microscopy for neck lymph node imaging in head and neck cancer.
     Oral Oncol. 2024;154:106862.
     

     >> Share

     
     
360. YAO Y, Ouyang Q, Wang S, Li K, et al
     Incorporation of PD-1 blockade into induction chemotherapy improved tumor response in patients with locoregionally advanced nasopharyngeal carcinoma in a retrospective patient cohort.
     Oral Oncol. 2024;154:106867.
     

     >> Share

     
     
361. RICARDO ELIAS DE MELO P, Agra Monteiro M, Vitoria de Araujo Lopes N, Silva Cunha JL, et al
     In response to the reply on 'Advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with teledentistry for enhanced patient outcomes'.
     Oral Oncol. 2024;154:106856.
     

     >> Share

     
     
362. COSTANTINO A, Haughey B, Zhu J, Mekhail T, et al
     Sinonasal squamous cell carcinoma in the United States: Temporal and geographic patterns associated with HPV testing and positivity.
     Oral Oncol. 2024;154:106855.
     

     >> Share

     
     
363. PEZZULLA D, Re A, Ferro M, Cilla S, et al
     Lower cranial nerve palsy after hypofractionated radiotherapy in a laryngeal cancer patient: A letter to the editor.
     Oral Oncol. 2024;154:106837.
     

     >> Share

     
     
364. ALVES DA MOTA SANTANA L, Gois Floresta L, Maciel Alves EV, Ribeiro Couto G, et al
     Reply to: Comment on "Advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with teledentistry for enhanced patient outcomes".
     Oral Oncol. 2024;154:106840.
     

     >> Share

     
     
365. HE S, Yu H, He L, Liu M, et al
     Risk factors associated with ototoxicity in long-term nasopharyngeal carcinoma survivors.
     Oral Oncol. 2024;154:106827.
     

     >> Share

     
     
366. VAZQUEZ FL, Coracin FL, Arantes KLBF, Ferigatto JL, et al
     An oral cancer screening program in Brazil: Analysis of seven years of outcome after its implementation in the suburban cities of Sao Paulo.
     Oral Oncol. 2024;154:106826.
     

     >> Share

     
     
367. DE FELICE F, Guerrero Urbano T
     Lower-neck sparing in patients with uninvolved neck nasopharyngeal carcinoma: Unquestioned benefit?
     Oral Oncol. 2024;154:106836.
     

     >> Share

     
     
368. HAN N, Zhou D, Ruan M, Yan M, et al
     Corrigendum to "Cancer cell-derived extracellular vesicles drive pre-metastatic niche formation of lymph node via IFNGR1/JAK1/STAT1-activated-PD-L1 expression on FRCs in head and neck cancer" [Oral Oncol. 145 (2023) 106524].
     Oral Oncol. 2024 May 9:106831. doi: 10.1016/j.oraloncology.2024.106831.
     

     >> Share

     
     
369. INVERNIZZI C, Da Silva Ribeiro Mota A, Barbe C, Bouazzi L, et al
     Prospective comparison of acute severe toxicities between smokers and non-smokers during radiotherapy for head and neck cancers.
     Oral Oncol. 2024;153:106833.
     

     >> Share

     
     
370. PADERNO A, Petrelli F, Lorini L, Capriotti V, et al
     The predictive role of PD-L1 in head and neck cancer: A systematic review and meta-analysis.
     Oral Oncol. 2024;153:106799.
     

     >> Share

     
     
371. LIU Y, Zuo ZC, Zeng XY, Ma J, et al
     Establishing subdivisions of M1 stage nasopharyngeal carcinoma based on decision tree classification: A multicenter retrospective study.
     Oral Oncol. 2024;153:106834.
     

     >> Share

     
     
372. XU Y, Xu T, Yao Q, Chen J, et al
     Individualized radiology screening for newly diagnosed nasopharyngeal carcinoma.
     Oral Oncol. 2024;153:106828.
     

     >> Share

     
     
373. ALMANGUSH A, Makitie AA, Leivo I
     Assessment of tumor-infiltrating lymphocytes in head and neck cancer: Clinical scenarios.
     Oral Oncol. 2024;153:106829.
     

     >> Share

     
     
374. DAS R, Misra SR
     Author's reply to comment on "awareness regarding oral cancer amongst the dental, medical, and nursing students: Is something lacking?".
     Oral Oncol. 2024;153:106832.
     

     >> Share

     
     
375. DHARMALINGAM JOTHINATHAN MK
     Outcomes of transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma with low rates of adjuvant therapy: A consecutive single-institution study from 2013 to 2020.
     Oral Oncol. 2024;152:106811.
     

     >> Share

     
     
376. POOJARI M, Madabhavi I, Desai S
     Extraskeletal Ewing's sarcoma of supraglottis: A rare case report.
     Oral Oncol. 2024;152:106789.
     

     >> Share

     
     
377. MELDGAARD JUSTESEN M, Kronberg Jakobsen K, Fenger Carlander AL, Hjordt Holm Larsen M, et al
     Outcomes of transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma with low rates of adjuvant therapy: A consecutive single-institution study from 2013 to 2020.
     Oral Oncol. 2024;152:106783.
     

     >> Share

     
     April 2024
378. TONSBEEK AM, Hundepool CA, Roubos J, Rijken B, et al
     Quality of life in 583 head and neck cancer survivors assessed with the FACE-Q head and neck cancer module.
     Oral Oncol. 2024;153:106813.
     

     >> Share

     
     
379. MICHIKAWA C, Gleber-Netto FO, Pickering CR, Rao X, et al
     Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer.
     Oral Oncol. 2024;153:106729.
     

     >> Share

     
     
380. FANG Q, Yuan J, Zhang X, Dai L, et al
     Oncologic and functional results between sentinel lymph node biopsy and elective neck dissection in cT1/2N0 maxillary squamous cell carcinoma.
     Oral Oncol. 2024;152:106810.
     

     >> Share

     
     
381. YEO BSY, Lee RS, Lim NE, Tan E, et al
     Efficacy and Safety of Cell-based Immunotherapy in The Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma - A Systematic Review and Meta-analysis.
     Oral Oncol. 2024;152:106786.
     

     >> Share

     
     
382. LI Y, Zhou Y, Zhao C, Liu L, et al
     The circadian clock gene, BMAL1, promotes radiosensitization in nasopharyngeal carcinoma by inhibiting the epithelial-to-mesenchymal transition via the TGF-beta1/Smads/Snail1 axis.
     Oral Oncol. 2024;152:106798.
     

     >> Share

     
     
383. RAMASAMY P, Sekaran S, Ganapathy D
     Oral cancer burden in tribal populations residing in India.
     Oral Oncol. 2024;152:106801.
     

     >> Share

     
     
384. SEKAR D
     Comment on betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study.
     Oral Oncol. 2024;152:106800.
     

     >> Share

     
     
385. SARAVANAN M
     Comment on "Nanomedicine, an emerging therapeutic strategy for oral cancer therapy".
     Oral Oncol. 2024;152:106806.
     

     >> Share

     
     
386. RICARDO ELIAS DE MELO P, Agra Monteiro M, Henrique Rocha Aragao H, Vitoria de Araujo Lopes N, et al
     Comment on "Awareness regarding oral cancer amongst the dental, medical, and nursing students: Is something lacking?".
     Oral Oncol. 2024;152:106802.
     

     >> Share

     
     
387. SMITH JD, Heft-Neal ME, Rosko AJ, Chepeha DB, et al
     Upfront neck dissection to guide single-modality therapy for early stage supraglottic squamous cell carcinoma.
     Oral Oncol. 2024;152:106803.
     

     >> Share

     
     
388. KONO M, Saito S, Rokugo M, Egloff AM, et al
     Enhanced oral versus flank lymph node T cell response parallels anti-PD1 efficacy in head and neck cancer.
     Oral Oncol. 2024;152:106795.
     

     >> Share

     
     
389. SEGNA E, Civita F, Denaro N, Beltramini GA, et al
     Cavernous sinus metastasis in head and neck cancer: Focus on oral squamous cell cancer.
     Oral Oncol. 2024;152:106784.
     

     >> Share

     
     
390. SIVAPERUMAL P, Ganapathy D, Kamala K
     Revolutionizing oral cancer treatment: Harnessing the potential of adaptive CARneg T cell therapy.
     Oral Oncol. 2024;152:106794.
     

     >> Share

     
     
391. RAJAKUMAR HK, Coimbatore Sathyabal V, Vivekanandam A, Nasrin Jabarulla K, et al
     Evaluation of nuclear morphometry in exfoliative cytology of buccal mucosa in patients with high risk of oral cancer.
     Oral Oncol. 2024;152:106793.
     

     >> Share

     
     
392. SARAVANAN M
     Comment on "The microbiome and oral cancer: More questions than answers".
     Oral Oncol. 2024;152:106792.
     

     >> Share

     
     
393. ARAGAO HHR, Monteiro MA, Lopes NVA, Cunha JLS, et al
     Comment on "Betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study".
     Oral Oncol. 2024;152:106788.
     

     >> Share

     
     
394. DAS R, Misra SR, Nayak A
     Awareness regarding oral cancer amongst the dental, medical, and nursing students: Is something lacking?
     Oral Oncol. 2024;152:106790.
     

     >> Share

     
     
395. XIAO X, Shi Z, Song Z
     Comment on circulatory mitochondrial DNA as a novel biomarker for head and neck cancers.
     Oral Oncol. 2024;152:106785.
     

     >> Share

     
     
396. GASNE C, Atallah S, Dauzier E, Thariat J, et al
     Twelve years after: The french national network on rare head and neck tumours (REFCOR).
     Oral Oncol. 2024;151:106762.
     

     >> Share

     
     
397. MALI SB
     Role of telemedicine in head neck cancer.
     Oral Oncol. 2024;151:106746.
     

     >> Share

     
     
398. MIRIMOGHADDAM M, Bohlouli B, Lai H, Viegas S, et al
     Trends and predictors of unplanned hospitalization among oral and oropharyngeal cancer patients; an 8-year population-based study.
     Oral Oncol. 2024;151:106742.
     

     >> Share

     
     March 2024
399. MEGAHED R, Prabhu AV, Mack DP, Gholami S, et al
     Re-irradiation of recurrent head and neck cancers using pulsed reduced dose rate radiotherapy: An institutional series.
     Oral Oncol. 2024;152:106778.
     

     >> Share

     
     
400. LORINI L, Gili R, Salvestrini V, Morelli I, et al
     De novo metastatic head and neck squamous cell carcinoma: Why does locoregional control "always" matter?
     Oral Oncol. 2024;152:106768.
     

     >> Share

     
     
401. XIROU V, Moutafi M, Bai Y, Nwe Aung T, et al
     An algorithm for standardization of tumor Infiltrating lymphocyte evaluation in head and neck cancers.
     Oral Oncol. 2024;152:106750.
     

     >> Share

     
     
402. HONG RL, Yen CJ, Lien MY, Cheng R, et al
     Betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study.
     Oral Oncol. 2024;152:106760.
     

     >> Share

     
     
403. FERRARI M, Mularoni F, Taboni S, Crosetti E, et al
     How reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? a multi-institutional study on 366 patients from the ARYFIX collaborative group.
     Oral Oncol. 2024;152:106744.
     

     >> Share

     
     
404. TOYA R, Fukugawa Y, Saito T, Matsuyama T, et al
     Radiation Therapy Oncology Group 8502 "QUAD shot" regimen using volumetric modulated arc therapy for incurable head and neck cancer.
     Oral Oncol. 2024;151:106752.
     

     >> Share

     
     
405. RUIZ-TORRES DA, Naegele S, Podury A, Wirth L, et al
     Immunotherapy time of infusion impacts survival in head and neck cancer: A propensity score matched analysis.
     Oral Oncol. 2024;151:106761.
     

     >> Share

     
     
406. SIMON L, Paly J, Park E, Samuels-Kalow M, et al
     Medicare dental coverage for patients with head and neck cancer: An opportunity in need of advocates.
     Oral Oncol. 2024 Mar 15:106754. doi: 10.1016/j.oraloncology.2024.106754.
     

     >> Share

     
     
407. RICARDO ELIAS DE MELO P, Agra Monteiro M, Vitoria de Araujo Lopes N, Silva Cunha JL, et al
     Comment on "advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with Teledentistry for Better Patient Outcomes".
     Oral Oncol. 2024;151:106758.
     

     >> Share

     
     
408. RAJANATHADURAI J, Sindya J, Madar IH, Perumal E, et al
     Exosomal immune checkpoint protein (PD-L1): Hidden player in PD-1/PD-L1 blockade immunotherapy resistance in oral cancer.
     Oral Oncol. 2024;151:106748.
     

     >> Share

     
     
409. ZUPANCIC M, Kostopoulou ON, Holzhauser S, Lukoseviciute M, et al
     Human papillomavirus (HPV) load is higher in HPVDNA/p16 positive than in HPVDNA positive/p16 negative oropharyngeal squamous cell carcinoma but does not differ significantly between various subsites or correlate to survival.
     Oral Oncol. 2024;151:106749.
     

     >> Share

     
     
410. FERRARO T, Pershad AR, Arora S, Lee E, et al
     The utility of ultrasonographic surveillance in management of a presumed branchial cleft cyst later confirmed HPV-associated oropharyngeal cancer.
     Oral Oncol. 2024;151:106743.
     

     >> Share

     
     
411. KIM DH, Lim ST, Kim HR, Kang EJ, et al
     Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study.
     Oral Oncol. 2024;151:106739.
     

     >> Share

     
     
412. SANTANA LADM, Floresta LG, Alves EVM, Melo LMR, et al
     Advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with teledentistry for enhanced patient outcomes.
     Oral Oncol. 2024;151:106741.
     

     >> Share

     
     
413. CHEN K, Shi M, Mo S, Liu T, et al
     Clinical features and prognostic factors of nasopharyngeal carcinoma with brain metastases.
     Oral Oncol. 2024;151:106738.
     

     >> Share

     
     
414. DING C, Dai DY, Luo ZK, Wang GY, et al
     Evaluation of a novel model incorporating serological indicators into the conventional TNM staging system for nasopharyngeal carcinoma.
     Oral Oncol. 2024;151:106725.
     

     >> Share

     
     
415. LU X, Zhang JL, Zhai X, Liu Q, et al
     A case report on a nasal and oral cavity involving large solitary fibrous tumor and comprehensive review of case literature.
     Oral Oncol. 2024;150:106715.
     

     >> Share

     
     
416. YOUNG RJ, Angel C, Bressel M, Pizzolla A, et al
     Characterising B cell expression and prognostic significance in human papillomavirus positive oropharyngeal cancer.
     Oral Oncol. 2024;150:106687.
     

     >> Share

     
     February 2024
417. VAN SCHAIK JE, van der Vegt B, Slagter-Menkema L, van der Laan BFAM, et al
     Identification of new head and neck squamous cell carcinoma molecular imaging targets.
     Oral Oncol. 2024;151:106736.
     

     >> Share

     
     
418. MELACHURI M, Kurukulasuriya C, Rumde P, Patel T, et al
     Treatment package time < 14 weeks improves recurrence free and disease specific survival in HPV positive OPC with high-risk features.
     Oral Oncol. 2024;151:106703.
     

     >> Share

     
     
419. AHMED AA, Sborchia M, Bye H, Roman-Escorza M, et al
     Mutation detection in saliva from oral cancer patients.
     Oral Oncol. 2024;151:106717.
     

     >> Share

     
     

Free Medical Abstracts
Privacy Policy
Sponsors
Share